var title_f6_2_6176="Contents: Pulmonary infections";
var content_f6_2_6176=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?8/24/8590\">",
"       Pulmonary, Critical Care, and Sleep Medicine",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pulmonary infections",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pulmonary infections",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Atypical pneumonia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/19/38199\">",
"           Clinical manifestations and diagnosis of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/58/32680\">",
"           Epidemiology and pathogenesis of Legionella infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/5/3162\">",
"           Mycoplasma pneumoniae infection in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/6/7270\">",
"           Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/14/8425\">",
"           Psittacosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/15/33015\">",
"           Treatment and prevention of Legionella infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bronchitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29289\">",
"           Acute bronchitis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/43/7866\">",
"           Management of infection in acute exacerbations of chronic obstructive pulmonary disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Community-acquired pneumonia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/33/29210\">",
"           Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/36/38473\">",
"           Community-acquired pneumonia in adults: Risk stratification and the decision to admit",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/26/26026\">",
"           Diagnostic approach to community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31514\">",
"           Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/38/23143\">",
"           Microbiology and pathogenesis of Streptococcus pneumoniae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/24/23945\">",
"           Nonresolving pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13386\">",
"           Pneumococcal pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21705\">",
"           Pneumococcal vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/48/1801\">",
"           Prognosis of community-acquired pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/5/81\">",
"           Resistance of Streptococcus pneumoniae to beta-lactam antibiotics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/18/3369\">",
"           Resistance of Streptococcus pneumoniae to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/15/19704\">",
"           Resistance of Streptococcus pneumoniae to the macrolides, azalides, lincosamines, and ketolides",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/24/24969\">",
"           Treatment of community-acquired pneumonia in adults in the outpatient setting",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/1/40986\">",
"           Treatment of community-acquired pneumonia in adults who require hospitalization",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fungal infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/5/38998\">",
"           Amphotericin B nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/26/1449\">",
"           Diagnosis and treatment of histoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/23/21881\">",
"           Diagnosis and treatment of pulmonary histoplasmosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39924\">",
"           Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/51/34616\">",
"           Epidemiology and clinical manifestations of invasive aspergillosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/51/39734\">",
"           Management of pulmonary sequelae and complications of coccidioidomycosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/24/42376\">",
"           Pathogenesis and clinical features of pulmonary histoplasmosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/10/12458\">",
"           Clinical manifestations and diagnosis of bronchiectasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/7/17524\">",
"           Clinical microbiology review: Respiratory tract infections",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/9/24729\">",
"           Lung abscess",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/24/23945\">",
"           Nonresolving pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/27/28089\">",
"           Parapneumonic effusion and empyema in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/48/1800\">",
"           Postoperative mediastinitis after cardiac surgery",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/5/37978\">",
"           Pulmonary complications of primary immunodeficiencies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/43/14005\">",
"           Renal disease in tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/11/17591\">",
"           Sputum cultures for the evaluation of bacterial pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/11/38073\">",
"           Treatment of bronchiectasis in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/5/15449\">",
"           Bacterial pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19093\">",
"           Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39924\">",
"           Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36310\">",
"           Parasitic pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22261\">",
"           Tuberculous pleural effusions in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Influenza",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/60/39880\">",
"           Antiviral drug resistance among seasonal influenza viruses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/31/35320\">",
"           Avian influenza vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/4/22599\">",
"           Clinical manifestations and diagnosis of avian influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/27/37305\">",
"           Clinical manifestations and diagnosis of pandemic H1N1 influenza ('swine influenza')",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/1/18456\">",
"           Clinical manifestations of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/25/5528\">",
"           Diagnosis of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15272\">",
"           Epidemiology of influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/2/31786\">",
"           Epidemiology of pandemic H1N1 influenza ('swine influenza')",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/48/14090\">",
"           Epidemiology, transmission, and pathogenesis of avian influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/34/2599\">",
"           Infection control measures to prevent seasonal influenza in healthcare settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/11/19640\">",
"           Pharmacology of antiviral drugs for influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/13/44249\">",
"           Prevention of seasonal influenza in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/8/37002\">",
"           Seasonal influenza vaccination in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/7/39032\">",
"           Treatment and prevention of avian influenza",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/21/38234\">",
"           Treatment and prevention of pandemic H1N1 influenza ('swine influenza')",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/46/22250\">",
"           Treatment of seasonal influenza in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nosocomial pneumonia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31017\">",
"           Aspiration pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24040\">",
"           Clinical presentation and diagnosis of ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/32/27145\">",
"           Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/57/12183\">",
"           Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/48/31494\">",
"           Pseudomonas aeruginosa pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/7/13433\">",
"           Risk factors and prevention of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6695\">",
"           The ventilator circuit and ventilator-associated pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/63/36858\">",
"           Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other respiratory viruses",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/38/617\">",
"           Parainfluenza viruses in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Parasitic infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36229\">",
"           Cutaneous larva migrans (creeping eruption)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/38/15977\">",
"           Epidemiology, pathogenesis, and clinical features of schistosomiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/28/42437\">",
"           Hookworm infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36310\">",
"           Parasitic pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11668\">",
"           Pulmonary manifestations of ascariasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/34/16935\">",
"           Toxocariasis: visceral and ocular larva migrans",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/54/15207\">",
"           Trichinellosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/30/2532\">",
"           Tropical filarial pulmonary eosinophilia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pneumocystis jiroveci (P. carinii)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/8/22665\">",
"           Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9289\">",
"           Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Severe acute respiratory syndrome (SARS)",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17753\">",
"           Severe acute respiratory syndrome (SARS)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Tuberculosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39673\">",
"           Clinical manifestations and evaluation of pulmonary tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18649\">",
"           Epidemiology of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Viral infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19093\">",
"           Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7050\">",
"           Respiratory syncytial virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15640\">",
"           Respiratory syncytial virus infection: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38327\">",
"           Respiratory syncytial virus infection: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/21/17753\">",
"           Severe acute respiratory syndrome (SARS)",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-93821F3066-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_2_6176=[""].join("\n");
var outline_f6_2_6176=null;
var title_f6_2_6177="3D ultrasound of displaced IUD";
var content_f6_2_6177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Three-dimensional ultrasound of displaced IUD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 444px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three-dimensional (3D) reconstructed ultrasound images can be helpful in assessing intrauterine contraceptive device (IUD) position. This 3D image shows the shaft of the IUD in the expected location. The right cross bar is slightly low, deviated downward.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6177=[""].join("\n");
var outline_f6_2_6177=null;
var title_f6_2_6178="Patient information: CPR for adults (The Basics)";
var content_f6_2_6178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16340\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/30/26086\">",
"         CPR position",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/39/34419\">",
"         Patient information: Sudden cardiac arrest (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: CPR for adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/cpr-for-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29400952\">",
"      <span class=\"h1\">",
"       What is CPR?",
"      </span>",
"      &nbsp;&mdash;&nbsp;CPR stands for &ldquo;cardiopulmonary resuscitation.&rdquo; It is a way to get blood and oxygen moving throughout the body of someone whose heart has stopped working.",
"      <br/>",
"     </p>",
"     <p>",
"      CPR can save a person&rsquo;s life. It can keep the brain and other organs from being damaged by lack of oxygen. It is something you do until the heart can be shocked back into action or until it becomes clear the person cannot be saved.",
"     </p>",
"     <p>",
"      The instructions for doing CPR on adults are different from the instructions for doing CPR on children. This article is about doing CPR on adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29400959\">",
"      <span class=\"h1\">",
"       How do I know if a person needs CPR?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you come across an adult who is passed out, tap the person forcefully and ask, &ldquo;Are you OK?&rdquo; If the person does not respond, is not breathing, or is breathing abnormally (gasping),",
"      <strong>",
"       call 9-1-1",
"      </strong>",
"      . Then start CPR. &nbsp;",
"     </p>",
"     <p>",
"      The person who is passed out and needs CPR is often called the &ldquo;victim.&rdquo; The person who does CPR is often called the &ldquo;rescuer.&rdquo; &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29400966\">",
"      <span class=\"h1\">",
"       What if I don&rsquo;t know how to do CPR?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can do CPR even if you have never done it before and have never been trained. All you have to do is press HARD AND FAST on the center of the victim&rsquo;s chest. It doesn&rsquo;t matter if you don&rsquo;t know what you are doing.",
"     </p>",
"     <p>",
"      Pressing on the chest for CPR is called doing &ldquo;compressions.&rdquo; To do compressions, make sure the victim is on a flat, solid surface. Then kneel over the victim, stack your hands on top of one another with both palms facing down, and lock your fingers together. Holding your arms straight, press on the center of the victim&rsquo;s chest with the heel of your bottom hand (",
"      <a class=\"graphic graphic_picture graphicRef73357 \" href=\"UTD.htm?25/30/26086\">",
"       picture 1",
"      </a>",
"      ). Use your body weight, rather than the strength of your arms, to press on the chest. Pushing like this squeezes the victim&rsquo;s heart and gets blood moving again. &nbsp;",
"     </p>",
"     <p>",
"      Make sure the victim&rsquo;s chest drops down at least 2 inches under your weight with each push. Between compressions, lift all pressure off the victim&rsquo;s chest so that his or her chest goes back to where it was. Keep pushing hard and fast on the center of the chest. The goal is to do at least 100 compressions a minute. &nbsp;",
"     </p>",
"     <p>",
"      Keep doing compressions until an ambulance comes or someone who is trained in healthcare takes over. Do not worry about breathing for the victim or doing anything besides compressions. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29400973\">",
"      <span class=\"h1\">",
"       Does everyone do CPR the same way?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. People trained in healthcare do CPR differently than other people. People trained in healthcare check a person&rsquo;s pulse before starting CPR. Then they follow 3 main steps, which are easy to remember based on the letters C-A-B:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        &ldquo;C&rdquo; stands for, &ldquo;Do chest",
"        <strong>",
"         compressions&rdquo;",
"        </strong>",
"        &mdash; For this part, the rescuer does 30 compressions as described above.",
"       </li>",
"       <li>",
"        &ldquo;A&rdquo; stands for, &ldquo;Check the",
"        <strong>",
"         airway&rdquo;",
"        </strong>",
"        &mdash; For this part, the rescuer checks the position of the victim&rsquo;s head and jaw to make sure the victim can breathe. If needed, the rescuer might move the victim&rsquo;s head or jaw to get the airway open. &nbsp;",
"       </li>",
"       <li>",
"        &ldquo;B&rdquo; stands for, &ldquo;Do rescue",
"        <strong>",
"         breathing&rdquo;",
"        </strong>",
"        &mdash; For this part, the rescuer holds the victim&rsquo;s nose shut and forms a seal over his or her mouth. Then the rescuer breathes into the victim&rsquo;s mouth to get some new air&mdash;with more oxygen&mdash;into his or her lungs. The rescuer gives 2 breaths this way and then switches back and forth between compressions and rescue breathing until an ambulance comes or someone else takes over.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29400980\">",
"      <span class=\"h1\">",
"       Have the guidelines on how to do CPR changed?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The American Heart Association (AHA) changed the guidelines about how to do CPR in 2010. It used to be that all rescuers were expected to check a victim&rsquo;s airway and give rescue breaths if the victim was not breathing. Now people who do not know CPR are advised to do &ldquo;hands-only&rdquo; CPR, meaning they do only chest compressions and do not worry about the airway or rescue breathing.",
"     </p>",
"     <p>",
"      People are sometimes afraid to do CPR, especially if they must do rescue breathing. Hands-only CPR is easier to do, and experts hope that people will be more comfortable doing it. The most important thing to do for someone whose heart has stopped is to get blood moving again. That&rsquo;s why compressions are so important and why it is better to do just compressions than to do nothing at all. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29401062\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=see_link\">",
"       Patient information: Sudden cardiac arrest (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/2/6178?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16340 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6178=[""].join("\n");
var outline_f6_2_6178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29400952\">",
"      What is CPR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29400959\">",
"      How do I know if a person needs CPR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29400966\">",
"      What if I don&rsquo;t know how to do CPR?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29400973\">",
"      Does everyone do CPR the same way?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29400980\">",
"      Have the guidelines on how to do CPR changed?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29401062\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/30/26086\">",
"      CPR position",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/39/34419?source=related_link\">",
"      Patient information: Sudden cardiac arrest (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_2_6179="MRI MTS T2";
var content_f6_2_6179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77659&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T2-weighted MR image showing mild left sided mesial temporal sclerosis in a round hippocampal variant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the decreased volume and abnormal increased T2 signal of the hippocampus (arrow) and atrophy of the left temporal lobe, including the white matter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6179=[""].join("\n");
var outline_f6_2_6179=null;
var title_f6_2_6180="TR beta molecule";
var content_f6_2_6180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77294&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 597px\">",
"   <div class=\"ttl\">",
"    Location of mutations in the TR",
"    <sub>",
"     &beta;",
"    </sub>",
"    molecule causing RTH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 577px; height: 499px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Schematic representation of TR",
"    <sub>",
"     &beta;",
"    </sub>",
"    and its functional domains for interaction with TREs (DNA-binding), with hormone (T3-binding), with activating and repressing cofactors, and with nuclear receptor partners (dimerization). Note their relationship to the three clusters of natural mutations. B) The T3-binding domain and distal end of the hinge region, which contain the three mutation clusters, are expanded and show the positions of CpG dinucleotide, which are mutational \"hot spots\" in the RT",
"    <sub>",
"     &beta;",
"    </sub>",
"    gene.",
"    <br>",
"     The location of 124 different mutations detected in 343 unrelated families (published and our unpublished data) are each indicated by a symbol. Identical mutations in members of unrelated families are indicated vertically by the same color and symbol. \"Cold regions\" are areas devoid of mutations associated with RTH. Amino acids are numbered consecutively starting at the amino terminus of the TR",
"     <sub>",
"      &beta;",
"     </sub>",
"     1 molecule according to the consensus statement of the First International Workshop on RTH [Beck-Peccoz 1993]. TR",
"     <sub>",
"      &beta;",
"     </sub>",
"     2 has 15 additional residues at the amino terminus.",
"     <div class=\"footnotes\">",
"      AF2: hormone-dependent activation function (12th amphipatic helix); RBE: corepressor-binding enhancer; RBI: corepressor-binding inhibitor; SSD: silencing subdomain; NucL: nuclear localization; SigM: signature motif.",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: WWW.THYROIDMANAGER.ORG, the comprehensive free on-line web textbook, Chapter 16d, by Samuel Refetoff, MD, version 7 June 2008.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6180=[""].join("\n");
var outline_f6_2_6180=null;
var title_f6_2_6181="Cefdinir: Pediatric drug information";
var content_f6_2_6181=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefdinir: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"    see \"Cefdinir: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/40/17028?source=see_link\">",
"    see \"Cefdinir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F147178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Omnicef&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Cephalosporin (Third Generation)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=see_link\">",
"      see \"Cefdinir: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children (&ge;6 months to 12 years):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otitis media or pharyngitis/tonsillitis: 14 mg/kg/day divided every 12 hours for 5-10 days or 14 mg/kg/day once daily for 10 days; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Skin and skin structure infection: 14 mg/kg/day divided twice daily for 10 days; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute maxillary sinusitis: 14 mg/kg/day divided every 12 hours for 10 days or 14 mg/kg/day once daily for 10 days; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute exacerbations of chronic bronchitis or pharyngitis/tonsillitis: 600 mg once daily for 10 days or 300 mg every 12 hours for 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Skin and skin structure infection or community-acquired pneumonia: 300 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acute maxillary sinusitis: 600 mg once daily for 10 days or 300 mg every 12 hours for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;6 months to 12 years: 7 mg/kg/dose once daily; maximum: 300 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 300 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients receiving hemodialysis: 300 mg or 7 mg/kg/dose starting at the conclusion of each hemodialysis session with subsequent doses every other day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnicef&reg;: 300 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for suspension, oral: 125 mg/5 mL (60 mL, 100 mL); 250 mg/5 mL (60 mL, 100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Omnicef&reg;: 125 mg/5 mL (60 mL [DSC], 100 mL [DSC]); 250 mg/5 mL (60 mL [DSC], 100 mL [DSC]) [contains sodium benzoate, sucrose 2.86 g/5 mL; strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May administer with or without food; administer with food if stomach upset occurs; administer cefdinir at least 2 hours before or after antacids or iron supplements; shake suspension well before use",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; reconstituted suspension stable for 10 days at room temperature",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Infections caused by susceptible organisms including",
"     <i>",
"      S. pneumoniae",
"     </i>",
"     (penicillin-susceptible strains only; inadequate activity against resistant pneumococcus),",
"     <i>",
"      H. influenzae",
"     </i>",
"     (including beta-lactamase-producing strains),",
"     <i>",
"      H. parainfluenzae",
"     </i>",
"     (including beta-lactamase-producing strains),",
"     <i>",
"      M. catarrhalis",
"     </i>",
"     (including beta-lactamase-producing strains),",
"     <i>",
"      S. aureus",
"     </i>",
"     (inactive against methicillin-resistant staphylococci), and",
"     <i>",
"      S. pyogenes",
"     </i>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FDA approved in Infants and Children &ge;6 months: Treatment of acute bacterial otitis media, acute maxillary sinusitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FDA approved in Adolescents and Adults: Treatment of community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F147202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Bicarbonate decreased, hyperglycemia, hyperphosphatemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urine leukocytes increased, urine pH increased, urine specific gravity increased, vaginal moniliasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophils increased, lymphocytes decreased/increased, platelets increased, PMN changes, WBC decreased/increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glycosuria, microhematuria, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: GGT increased, lactate dehydrogenase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic vasculitis, amylase increased, anaphylaxis, anorexia, asthma, AST increased, bilirubin increased, bleeding tendency, bloody diarrhea, BUN increased, cardiac failure, chest pain, cholestasis, coagulation disorder, conjunctivitis, constipation, cutaneous moniliasis, disseminated intravascular coagulation (DIC), dizziness, dyspepsia, enterocolitis (acute), eosinophilic pneumonia, erythema multiforme, erythema nodosum, exfoliative dermatitis, facial edema, fever, flatulence, fulminant hepatitis, granulocytopenia, hemoglobin decreased, hemolytic anemia, hemorrhagic colitis, hepatic failure, hepatitis (acute), hyperkalemia, hyperkinesia, hypertension, hypocalcemia, hypophosphatemia, idiopathic thrombocytopenia purpura, ileus, insomnia, interstitial pneumonia (idiopathic), involuntary movement, jaundice, laryngeal edema, leukopenia, leukorrhea, loss of consciousness, maculopapular rash, melena, moniliasis, monocytes increased, myocardial infarction, nephropathy, pancytopenia, peptic ulcer, pneumonia (drug-induced), pruritus, pseudomembranous colitis, renal failure (acute), respiratory failure (acute), rhabdomyolysis, serum sickness, shock, somnolence, Stevens-Johnson syndrome, stomatitis, stools abnormal, thrombocytopenia, toxic epidermal necrolysis, upper GI bleed, urine specific gravity decreased,  weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional reactions reported with other cephalosporins: Agranulocytosis, angioedema, aplastic anemia, asterixis, encephalopathy, hemorrhage, interstitial nephritis, neuromuscular excitability, PT prolonged, seizure, superinfection, and toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefdinir, any component, or cephalosporins",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal function, history of colitis, or in penicillin-sensitive patients; modify dosage in patients with severe renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pseudomembranous colitis has been reported with cefdinir; prolonged use may result in superinfection; serum sickness-like reactions have been reported with signs and symptoms occurring after a few days of therapy and resolving a few days after drug discontinuation. Do not use in patients with immediate-type hypersensitivity reactions to penicillin. If an allergic reaction occurs, discontinue cefdinir. Powder for oral suspension contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; avoid use of cefdinir products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Cefdinir. Specifically, Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron-containing multivitamins when possible. Separating doses by several hours may minimize interaction. Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1045915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Total absorption is not affected by food. Iron-fortified infant formula has no significant effect on cefdinir absorption (cefdinir can be administered with iron-fortified infant formula)",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F854704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic events have not been observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate renal function before and during therapy; with prolonged therapy, monitor coagulation tests, CBC, liver function test periodically, and number and type of stools/day for diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins resulting in disruption of cell wall synthesis and cell lysis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: High-fat meal decreases extent of absorption by 10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Penetrates into blister fluid, middle ear fluid, tonsils, sinus, and lung tissues",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 6 months to 12 years: 0.67 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: 0.35 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules: 16% to 21%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suspension: 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: 1.7 (&plusmn; 0.6) hours with normal renal function",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 11.6% to 18.4% of a dose is excreted unchanged in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: &sim;63% is removed by hemodialysis (4 hours duration)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/40/17028?source=see_link\">",
"      see \"Cefdinir: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report persistent diarrhea to physician; may discolor stools red if taken with iron",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1045913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral suspension contains 2.86 g of sucrose per 5 mL.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;,",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2011, 53(7):e25-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6181/abstract-text/21880587/pubmed\" id=\"21880587\" target=\"_blank\">",
"        21880587",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein JO and McCracken GH Jr, &ldquo;Summary: Role of a New Oral Cephalosporin, Cefdinir, for Therapy of Infections of Infants and Children,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2000, 19(12 Suppl):S181-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6181/abstract-text/11144402/pubmed\" id=\"11144402\" target=\"_blank\">",
"        11144402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry CM  and Scott LJ, \"Cefdinir: A Review of Its Use in the Management of Mild-to-Moderate Bacterial Infections,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 2004, 64(13):1433-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6181/abstract-text/15212560/pubmed\" id=\"15212560\" target=\"_blank\">",
"        15212560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13125 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-60.18.131.125-92069A6D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6181=[""].join("\n");
var outline_f6_2_6181=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147178\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045906\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045898\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147161\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147146\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045909\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045902\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045908\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147202\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045912\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045897\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045896\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298986\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147155\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045915\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147157\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F854704\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045905\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045895\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045911\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045904\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045913\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13125\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13125|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/21/5461?source=related_link\">",
"      Cefdinir: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/40/17028?source=related_link\">",
"      Cefdinir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_2_6182="Atomoxetine: Patient drug information";
var content_f6_2_6182=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Atomoxetine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=see_link\">",
"     see \"Atomoxetine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=see_link\">",
"     see \"Atomoxetine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F137799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Strattera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Atomoxetine&reg;;",
"     </li>",
"     <li>",
"      Mylan-Atomoxetine;",
"     </li>",
"     <li>",
"      PMS-Atomoxetine;",
"     </li>",
"     <li>",
"      Sandoz-Atomoxetine;",
"     </li>",
"     <li>",
"      Strattera&reg;;",
"     </li>",
"     <li>",
"      Teva-Atomoxetine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700203",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Children and teenagers: Watch your child closely for a want to harm him/herself. Ask your child to talk with you if he/she is planning to harm him/herself. Take your child to the nearest ER (emergency room) if he/she wants to harm him/herself. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat attention deficit problems with hyperactivity. It may take 8 weeks to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to atomoxetine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3854479",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, very bad heart disease, high blood pressure, or pheochromocytoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697797",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have some heart tests before starting this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697133",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a fast heartbeat, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696635",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause high blood pressure, nervousness, shakiness, a fast heartbeat, and anxiety.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026595\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699005",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad problems with how you act.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698663",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699032",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696213",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug early in the day to stop sleep problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11042 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-E85F879F22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6182=[""].join("\n");
var outline_f6_2_6182=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F137799\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855136\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026586\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026588\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026587\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026592\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026593\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026595\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026590\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026591\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026596\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026597\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/62/999?source=related_link\">",
"      Atomoxetine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/46/12007?source=related_link\">",
"      Atomoxetine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_2_6183="Dofetilide: Drug information";
var content_f6_2_6183=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dofetilide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/18/28964?source=see_link\">",
"    see \"Dofetilide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F162348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tikosyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F162349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tikosyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F162368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiarrhythmic Agent, Class III",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F162351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     QT or QT",
"     <sub>",
"      c",
"     </sub>",
"     must be determined prior to first dose. If QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;440 msec (&gt;500 msec in patients with ventricular conduction abnormalities), dofetilide is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antiarrhythmic:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Initial: 500 mcg twice daily. Initial dosage must be adjusted in patients with estimated Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute (see dosage adjustment in renal impairment). Dofetilide may be initiated at lower doses than recommended based on physician discretion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Modification of dosage in response to",
"      <b>",
"       initial",
"      </b>",
"      dose:",
"     </i>",
"     QT",
"     <sub>",
"      c",
"     </sub>",
"     interval should be measured 2-3 hours after the initial dose. If the QT",
"     <sub>",
"      c",
"     </sub>",
"     is &gt;15% of baseline, or if the QT",
"     <sub>",
"      c",
"     </sub>",
"     is &gt;500 msec (550 msec in patients with ventricular conduction abnormalities), dofetilide should be reduced. If the starting dose was 500 mcg twice daily, then reduce to 250 mcg twice daily. If the starting dose was 250 mcg twice daily, then reduce to 125 mcg twice daily. If the starting dose was 125 mcg twice daily, then reduce to 125 mcg once daily. If at any time after the second dose is given the QT",
"     <sub>",
"      c",
"     </sub>",
"     is &gt;500 msec (550 msec in patients with ventricular conduction abnormalities), dofetilide should be discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F162352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No specific dosage adjustments are recommended based on age; however, careful assessment of renal function is particularly important in this population.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F162353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Using the Modification of Diet in Renal Disease (MDRD) equation and subsequent eGFR to determine dose may lead to overestimation of creatinine clearance and overdose of medication; use only the Cockcroft-Gault equation to estimate creatinine clearance (Denetclaw, 2011). Use actual body weight when using the Cockcroft-Gault equation to calculate creatinine clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: Administer 500 mcg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-60 mL/minute: Administer 250 mcg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute: Administer 125 mcg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute: Contraindicated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F162354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments required in Child-Pugh class A and B; patients with severe hepatic impairment were not studied.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F162327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tikosyn&reg;: 125 mcg, 250 mcg, 500 mcg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F162313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11233706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a requirement of the REMS program, access to this medication is restricted. Tikosyn&reg; is only available to prescribers and hospitals that have confirmed their participation in a designated Tikosyn&reg; Education Program. The program provides comprehensive education about the importance of in-hospital treatment initiation and individualized dosing.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     T.I.P.S. is the Tikosyn&reg; In Pharmacy System designated to allow retail pharmacies to stock and dispense Tikosyn&reg; once they have been enrolled. A participating pharmacy must confirm receipt of the T.I.P.S. program materials and educate its pharmacy staff about the procedures required to fill an outpatient prescription for Tikosyn&reg;. The T.I.P.S. enrollment form is available at www.tikosyn.com. Tikosyn&reg; is only available from a special mail order pharmacy, and enrolled retail pharmacies. Pharmacists must verify that the hospital/prescriber is a confirmed participant before Tikosyn&reg; is provided. For participant verification, the pharmacist may call 1-800-788-7353 or use the web site located at www.tikosynlist.com. Further details and directions on the program are provided at www.tikosyn.com.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Dofetilide therapy must be initiated/adjusted in a hospital setting with proper monitoring under the guidance of experienced personnel.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F13160861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM266314.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM266314.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F162328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance of normal sinus rhythm in patients with chronic atrial fibrillation/atrial flutter of longer than 1-week duration who have been converted to normal sinus rhythm; conversion of atrial fibrillation and atrial flutter to normal sinus rhythm",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13657230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alternative antiarrhythmic for the treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy (HCM)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13934279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dofetilide may be confused with defibrotide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F162366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Supraventricular arrhythmia patients:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8%), insomnia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Ventricular tachycardia (2.6% to 3.7%), chest pain (10%), torsade de pointes (3.3% in HF patients and 0.9% in patients with a recent MI; up to 10.5% in patients receiving doses in excess of those recommended). Torsade de pointes occurs most frequently within the first 3 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (5%), diarrhea (3%), abdominal pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory tract infection (7%), dyspnea (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: CVA, facial paralysis, flaccid paralysis, migraine, paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: AV block (0.4% to 1.5%), bundle branch block (0.1% to 0.5%), heart block (0.1% to 0.5%), ventricular fibrillation (0% to 0.4%),  bradycardia, cardiac arrest, edema, MI, sudden death, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Angioedema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Liver damage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F162332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dofetilide or any component of the formulation; patients with congenital or acquired long QT syndromes, do not use if baseline QT interval or QT",
"     <sub>",
"      c",
"     </sub>",
"     is &gt;440 msec (500 msec in patients with ventricular conduction abnormalities); severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute [Cockcroft-Gault method]); concurrent use with verapamil, cimetidine, hydrochlorothiazide (alone or in combinations), trimethoprim (alone or in combination with sulfamethoxazole), itraconazole (according to itraconazole prescribing information) ketoconazole, prochlorperazine, or megestrol",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F162317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Proarrhythmic effects: Watch for proarrhythmic effects; monitor and adjust dose to prevent QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation. Risk of torsade de pointes (TdP) significantly increases with doses greater than the maximum dose of 500 mcg twice daily. The risk of TdP may be higher in certain patient subgroups (eg, patients with heart failure). Most episodes of TdP occur within the first 3 days of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Appropriate use: Reserve for patients who are highly symptomatic with atrial fibrillation/atrial flutter.",
"     <b>",
"      [U.S. Boxed Warning]:  Must be initiated (or reinitiated) in a setting with continuous monitoring and staff familiar with the recognition and treatment of life-threatening arrhythmias. Patients must be monitored with continuous ECG for a minimum of 3 days,",
"     </b>",
"     or for a minimum of 12 hours after electrical or pharmacological cardioversion to normal sinus rhythm, whichever is greater. Patients should be readmitted for continuous monitoring if dosage is later increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction disturbances: Use with caution in patients with second or third-degree heart block and/or sick sinus syndrome unless a functional pacemaker is in place; these patients were not included in phase 3 clinical trials. However, no effect on AV nodal conduction seen in patients with normal conduction and those with pre-existing heart block and/or sick sinus syndrome. Defibrillation threshold is reduced in patients with ventricular tachycardia or ventricular fibrillation undergoing implantation of a cardioverter-defibrillator device.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment;",
"     <b>",
"      dose adjustment required for patients with Cl",
"      <sub>",
"       cr",
"      </sub>",
"      &le;60 mL/minute.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval is not recommended. Hold class I or class III antiarrhythmics for at least three half-lives prior to starting dofetilide; may use in patients previously on amiodarone therapy only if serum amiodarone level is &lt;0.3 mg/L or if amiodarone was discontinued &ge;3 months ago.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-depleting diuretics: Risk of hypokalemia and/or hypomagnesemia may be increased by potassium-depleting diuretics, increasing the risk of malignant arrhythmias such as TdP.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In the treatment of atrial fibrillation, avoid antiarrhythmics as first-line treatment. In older adults, data suggests rate control may provide more benefits than risks compared to rhythm control for most patients (Beers Criteria).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F162363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F162322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AMILoride: May increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Dofetilide. This is likely via inhibition of dofetilide renal tubular secretion (primarily) and inhibition of dofetilide metabolism.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     EriBULin: May enhance the QTc-prolonging effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the QTc-prolonging effect of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Megestrol: May increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: May increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prochlorperazine: May increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Management: Concurrent use of propafenone with quinidine, amiodarone, or other class IA or class III antiarrhythmics should be avoided.  Treatment with such agents should be withheld for at least 5 half-lives prior to initiation of propafenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: May enhance the arrhythmogenic effect of Dofetilide. Saquinavir may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triamterene: May increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the excretion of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F162344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: St John's wort may decrease dofetilide levels. Avoid ephedra (may worsen arrhythmia).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F162323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F162335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dofetilide has been shown to adversely affect",
"     <i>",
"      in utero",
"     </i>",
"     growth, organogenesis, and survival of rats and mice. There are no adequate and well-controlled studies in pregnant women. Dofetilide should be used with extreme caution in pregnant women and in women of childbearing age only when the benefit to the patient unequivocally justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F162358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F162334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Tikosyn Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     125 mcg (40): $199.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mcg (40): $199.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mcg (40): $199.06",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F162325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG monitoring with attention to QT (if heart rate &lt;60 beats per minute) or QT",
"     <sub>",
"      c",
"     </sub>",
"     and occurrence of ventricular arrhythmias, baseline serum creatinine and changes in serum creatinine. Upon initiation (or reinitiation) continuous ECG monitoring recommended for a minimum of 3 days, or for at least 12 hours after electrical or pharmacological conversion to normal sinus rhythm, whichever is greater. Check serum potassium and magnesium levels at baseline and throughout therapy especially if on medications where these electrolyte disturbances can occur, or if patient has a history of hypokalemia or hypomagnesemia. QT or QT",
"     <sub>",
"      c",
"     </sub>",
"     must be monitored at baseline prior to the first dose and 2-3 hours afterwards. If at baseline, QT",
"     <sub>",
"      c",
"     </sub>",
"     &gt;440 msec (&gt;500 msec in patients with ventricular conduction abnormalities), dofetilide is contraindicated. If dofetilide initiated, QT",
"     <sub>",
"      c",
"     </sub>",
"     interval must be determined 2-3 hours after each subsequent dose of dofetilide for in-hospital doses 2-5. Thereafter, QT or QT",
"     <sub>",
"      c",
"     </sub>",
"     and creatinine clearance should be evaluated every 3 months. If at any time during therapy after the second dose the measured QT",
"     <sub>",
"      c",
"     </sub>",
"     is &gt;500 msec (550 msec in patients with ventricular conduction abnormalities), dofetilide should be discontinued.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F162336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dicetel (AR, AT, BE, BR, CH, CL, CO, CZ, EC, FR, GR, HN, IT, KP, PT, TH, TW, UY, VE);",
"     </li>",
"     <li>",
"      Eldicet (CN, PH, PY);",
"     </li>",
"     <li>",
"      Periplum (PE);",
"     </li>",
"     <li>",
"      Tikosyn (NZ);",
"     </li>",
"     <li>",
"      Tintel (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F162316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vaughan Williams Class III antiarrhythmic activity. Blockade of the cardiac ion channel carrying the rapid component of the delayed rectifier potassium current. Dofetilide has no effect on sodium channels, adrenergic alpha-receptors, or adrenergic beta-receptors. It increases the monophasic action potential duration due to delayed repolarization. The increase in the QT interval is a function of prolongation of both effective and functional refractory periods in the His-Purkinje system and the ventricles. Changes in cardiac conduction velocity and sinus node function have not been observed in patients with or without structural heart disease. PR and QRS width remain the same in patients with pre-existing heart block and or sick sinus syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F162331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4, but low affinity for it; metabolites formed by N-dealkylation and N-oxidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~10 hours; prolonged with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Fasting: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80%; 80% as unchanged drug, 20% as inactive or minimally active metabolites); renal elimination consists of glomerular filtration and active tubular secretion via cationic transport system",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Choy AM, Darbar D, Dell'Orto S, et al, &ldquo;Exaggerated QT Prolongation After Cardioversion of Arterial Fibrillation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 34(2):396-401.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/10440151/pubmed\" id=\"10440151\" target=\"_blank\">",
"        10440151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Denetclaw TH, Oshima N, and Dowling TC, &ldquo;Dofetilide Dose Calculation Errors in Elderly Associated With Use of the Modification of Diet in Renal Disease Equation,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2011, 45(7-8):e44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/21712508/pubmed\" id=\"21712508\" target=\"_blank\">",
"        21712508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Falk RH, Pollak A, Singh SN, et al, &ldquo;Intravenous Dofetilide, A Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter. Intravenous Dofetilide Investigators,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1997, 29(2):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/9014993/pubmed\" id=\"9014993\" target=\"_blank\">",
"        9014993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      K&oslash;ber L, Bloch Thomsen PE, M&oslash;ller M, et al, \"Effect of Dofetilide in Patients With Recent Myocardial Infarction and Left-Ventricular Dysfunction: A Randomised Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9247):2052-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/11145491/pubmed\" id=\"11145491\" target=\"_blank\">",
"        11145491",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mounsey JP and DiMarco JP, &ldquo;Dofetilide,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(21):2665-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/11085972/pubmed\" id=\"11085972\" target=\"_blank\">",
"        11085972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naccarelli GV, Wolbrette DL, Khan M, et al, &ldquo;Old and New Antiarrhythmic Drugs for Converting and Maintaining Sinus Rhythm in Atrial Fibrillation: Comparative Efficacy and Results of Trials,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2003, 91(6A):15D-26D.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/12670638/pubmed\" id=\"12670638\" target=\"_blank\">",
"        12670638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Norgaard BL, Wachtell K, Christensen PD, et al, &ldquo;Efficacy and Safety of Intravenously Administered Dofetilide in Acute Termination of Atrial Fibrillation and Flutter: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 1999, 137(6):1062-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/10347332/pubmed\" id=\"10347332\" target=\"_blank\">",
"        10347332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prystowsky EN, Benson DW Jr, Fuster V, et al, &ldquo;Management of Patients With Atrial Fibrillation: A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1996, 93(6):1262-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/8653857/pubmed\" id=\"8653857\" target=\"_blank\">",
"        8653857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh S, Zoble RG, Yellen L, et al, &ldquo;Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2000, 102(19):2385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/11067793/pubmed\" id=\"11067793\" target=\"_blank\">",
"        11067793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Torp-Pederson C, Moller M, Bloch-Thomsen PE, et al, &ldquo;Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(12):857-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/10486417/pubmed\" id=\"10486417\" target=\"_blank\">",
"        10486417",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/2/6183/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8904 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6183=[""].join("\n");
var outline_f6_2_6183=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708707\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162348\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162349\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162368\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162351\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162352\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162353\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162354\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162327\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162313\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11233706\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13160861\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162328\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13657230\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13934279\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162366\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162332\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162317\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162363\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162322\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162344\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162323\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162335\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162358\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162334\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162325\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162336\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162316\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F162331\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8904\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8904|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/18/28964?source=related_link\">",
"      Dofetilide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_2_6184="EPS tracing AVNRT dual AVN pathways II";
var content_f6_2_6184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F72161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F72161&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Electrophysiologic study (EPS) in a patient with atrioventricular nodal reentrant tachycardia and dual AV nodal pathways",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tracing shows three surface ECG leads (I, II, V1) and intracardiac recordings from the high right atrium (HRA), bundle of His (HIS), right ventricular apex (RVA), and coronary sinus (CS). During atrial pacing (S1) at a cycle length of 600 ms (100 beats per minute); the AH interval is 120 ms. An atrial premature beat (S2) is added at a coupling cyle of 410 ms; this results in a prolongation of the PR interval and increase in the AH interval to 242 ms, which represents a 60 ms increase compared to the AH when a premature beat was added with a coupling interval of 420 ms. This represents a \"jump\" due to a shift of AV nodal conduction from the fast to slow AV nodal pathway. Since the fast pathway has time to recover, there is retrograde VA conduction via the fast pathway, resulting in the occurrence of a retrograde His depolarization (HIS \"A\") and an atrial echo beat at the CS os area (CS 10-9).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6184=[""].join("\n");
var outline_f6_2_6184=null;
var title_f6_2_6185="Normal neutrophil development and kinetics";
var content_f6_2_6185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Normal neutrophil development and kinetics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/2/6185/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6185/contributors\">",
"     Thomas D Coates, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/2/6185/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6185/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6185/contributors\">",
"     Laurence A Boxer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/2/6185/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6185/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6185/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/2/6185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circulating blood cells are formed in bone marrow through a process called hematopoiesis. The bone marrow has an enormous production capacity; it is estimated that 10",
"    <sup>",
"     10",
"    </sup>",
"    erythrocytes and 10",
"    <sup>",
"     8",
"    </sup>",
"    to 10",
"    <sup>",
"     9",
"    </sup>",
"    leukocytes are produced per hour in the steady state. Furthermore, while cell numbers are maintained within fairly narrow limits, they can be greatly amplified on demand.",
"   </p>",
"   <p>",
"    These huge cell numbers are immediate descendants of maturing precursors that arise from a smaller pool of progenitors. The progenitors in turn arise from an even smaller pool of hematopoietic stem cells that are thought to be mostly in a resting or non-dividing state and have the capacity to self-renew (and thus maintain their numbers).",
"   </p>",
"   <p>",
"    Hematopoietic stem cells are multipotent and have the capacity to differentiate into the cells of all 10 blood lineages &mdash; erythrocytes, platelets, neutrophils, eosinophils, basophils, monocytes, T and B lymphocytes, natural killer cells, and dendritic cells (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .) The multipotent stem cell can give rise to the myeloid stem cell, also referred to as CFU-GEMM because it is the precursor to lineage-specific stem cells for Granulocytes, Erythrocytes, Monocytes, and Megakaryocytes. CFU stands for colony forming units that grow as pure colonies of 50 to 100 cells after 7 to 14 days in semisolid medium at 37&ordm;C.",
"   </p>",
"   <p>",
"    The CFU-GEMM can be identified using CD34 and HLA-DR as markers. Some human myeloid stem cells express an additional marker, ie, CD64, which identifies a specific stem cell dedicated to granulocyte and monocyte development. This CD34, HLA-DR, and CD-64 positive stem cell is called CFU-GM because colonies of mature Granulocytes and",
"    <span class=\"nowrap\">",
"     Monocytes/Macrophages",
"    </span>",
"    form when the stem cell is cultured in semisolid medium with appropriate growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The major growth factors required for maturing CFU-GEMM into CFU-GM are Steel factor (also called stem cell factor or c-kit ligand), interleukin (IL)-3, IL-6 (induced by IL-3), Flt3 ligand, and granulocyte-macrophage colony-stimulating factor (GM-CSF) (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"UTD.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ). GM-CSF receptor expression begins in immature precursor cells and is progressively increased during differentiation into mature granulocytes and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neutrophil development and kinetics will be reviewed here. The factors responsible for the regulation of myelopoiesis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=see_link\">",
"     \"Regulation of myelopoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MORPHOLOGY OF DEVELOPING NEUTROPHILS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six stages of polymorphonuclear neutrophil (PMN) development are characterized by six morphological criteria of developing myeloid cells, as seen by light microscopy. These criteria are: relative size, nuclear volume, chromatin density, prominence of nucleoli, granule number, and cytoplasmic staining. The ultrastructure of granulocytes is of biologic importance but contributes little to identifying the stages of development based upon morphologic criteria utilizing Wright-Giemsa polychrome stained bone marrow smear. In general, cell maturation is accompanied by reduction in cell size, diminished cell volume, increased chromatin condensation of the nucleus, loss of nuclear nucleoli, appearance of cytoplasmic granules, and change in cytoplasmic basophilia (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"UTD.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The factors determining the regulation of myeloid differentiation through these developmental stages continue to be a focus of research. This process is regulated by a wide array of transcriptional regulatory proteins leading to a biochemical and morphological progression in the same manner as that occurring in erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Myeloblast stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myeloblast is the earliest myeloid precursor recognizable with the light microscope in the bone marrow. The size is medium (15 to 20 microns in diameter), the nucleus is large and round with finely granular chromatin, nucleoli are present, granules are usually absent by light microscopy, and cytoplasm is scanty (",
"    <a class=\"graphic graphic_picture graphicRef74014 \" href=\"UTD.htm?37/11/38067\">",
"     picture 1",
"    </a>",
"    ). Electron microscopy reveals numerous round or oval mitochondria (&lt;1 micron in diameter), Golgi apparatus with a centriole, vesicles and sacs, many free cytoplasmic ribosomes and free polyribosomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Promyelocyte stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Promyelocytes are larger than myeloblasts and myelocytes (&gt;20 microns). The nucleus, nuclear chromatin, and nucleoli resemble myeloblasts but the cardinal feature is the presence of many violet stained granules with either a dense or coarse pattern often obscuring other cell landmarks (",
"    <a class=\"graphic graphic_picture graphicRef73480 \" href=\"UTD.htm?21/25/21908\">",
"     picture 2",
"    </a>",
"    ). These so-called azurophilic or primary granules measure 0.8 microns in diameter and are homogeneous, dense, and round to ovoid in shape and are bounded by a unit membrane.",
"   </p>",
"   <p>",
"    Azurophilic granules are made primarily by promyelocytes and contain a variety of bactericidal cationic proteins, proteolytic enzymes, and myeloperoxidase (often used as a marker for azurophilic granules) (",
"    <a class=\"graphic graphic_table graphicRef57400 \" href=\"UTD.htm?41/7/42109\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]; myeloperoxidase synthesis can also be demonstrated in myeloblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/13\">",
"     13",
"    </a>",
"    ]. Electron microscopy has shown that the prototypic protein myeloperoxidase is synthesized and packaged into storage granules by the pathway defined for other secretory proteins, ie, through endoplasmic reticulum to Golgi complex via vesicles to granules.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myelocyte stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelocyte is the last myeloid precursor capable of mitosis. Three cell divisions take place in the myelocyte pool; with each division, the cells change in size, shape, and color. Myelocyte progeny are progressively smaller, being reduced in diameter from &gt;20 microns to 14 microns. During myelocyte development, specific (or secondary) granules are synthesized, while the primary azurophilic granules are distributed throughout the myelocyte pool [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific granules are a marker of commitment to terminal myeloid differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/5\">",
"     5",
"    </a>",
"    ]. These granules are smaller (0.5 microns), more numerous, and less dense than primary azurophilic granules, and are difficult to see by light microscopy; they fill the cytosol with proteins that stain pale pink or lilac. They contain a variety of adhesive proteins including lactoferrin (often used as a marker for these granules) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/10\">",
"     10",
"    </a>",
"    ], the beta 2 integrin",
"    <span class=\"nowrap\">",
"     CD11/CD18,",
"    </span>",
"    the cytochrome",
"    <span class=\"nowrap\">",
"     b/gp91",
"     <sup>",
"      phox",
"     </sup>",
"    </span>",
"    component of the NADPH oxidase, binding protein for cobalamin, and unique PMN marker antigens (",
"    <a class=\"graphic graphic_table graphicRef57400 \" href=\"UTD.htm?41/7/42109\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As the myelocyte divides and matures, the nucleus becomes smaller and irregularly round, nuclear chromatin becomes coarse and clumped, and nucleoli are sparse to absent (",
"    <a class=\"graphic graphic_picture graphicRef54089 \" href=\"UTD.htm?1/7/1138\">",
"     picture 3",
"    </a>",
"    ). A pink region where specific granules are beginning to form is evident on the flattened side of the nucleus of smaller, more mature myelocytes. The nuclear to cytoplasmic ratio is reduced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metamyelocyte stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metamyelocytes are slightly smaller than myelocytes. During metamyelocyte development, the cytoplasm resembles that of the mature PMN and band forms and is uniformly pink; granules are finely dispersed throughout the cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef59197 \" href=\"UTD.htm?25/60/26563\">",
"     picture 4",
"    </a>",
"    ). The nucleus is indented like a kidney bean and the nuclear chromatin is coarse, clumped, and condensed peripherally.",
"   </p>",
"   <p>",
"    The metamyelocyte cannot divide, and further maturation consists predominantly of nuclear elongation and segmentation. The cell lacks nucleoli, polyribosomes, and endoplasmic reticulum necessary for ongoing protein synthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Band form",
"    </span>",
"    &nbsp;&mdash;&nbsp;The band form is also called the stab form or juvenile form because the nucleus is nonsegmented and elongated, taking the shape of a horseshoe (",
"    <a class=\"graphic graphic_picture graphicRef82140 \" href=\"UTD.htm?16/42/17060\">",
"     picture 5",
"    </a>",
"    ). No nuclear lobulations are evident, although constrictions may be visible. The nuclear chromatin is aggregated into evenly arranged clumps. The cytoplasm is like that of the mature PMN with pink staining and fine azure bluish granules; the proportion of azurophilic primary to specific secondary granules based upon cytohistochemistry is about 1:2 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/14\">",
"     14",
"    </a>",
"    ]. These cells also contain gelatinase or tertiary granules, which are a marker of terminal neutrophil differentiation (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Band forms are fully functional phagocytes and normally comprise 3 to 5 percent of the differential count. They should be included when calculating (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) the absolute neutrophil count (ANC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Polymorphonuclear neutrophil",
"    </span>",
"    &nbsp;&mdash;&nbsp;The PMN or segmented neutrophil is the end-stage of full maturation of the granulocyte. The mature PMN is of uniform size (13 microns in diameter). The nucleus is segmented into two to five (mean equals three) lobes connected by thin chromatin strands (",
"    <a class=\"graphic graphic_picture graphicRef60666 \" href=\"UTD.htm?30/37/31316\">",
"     picture 6",
"    </a>",
"    ). The nuclear chromatin is coarse, clumped and stains deep purple with Wright-Giemsa. Five to 10 percent of PMN contain nuclear irregularities such as nicks, appendices, fibrillar bodies and bridges. In addition, approximately 3 percent of PMN in normal females have a drumstick oval mass of dense chromatin 1.5 micron in size called a Barr body attached to one of the lobes by a slender filament [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cytoplasm contains fine azure bluish granules and predominant specific secondary granules, which are finely dispersed and stain the cytoplasm faintly pink. The granules show considerable heterogeneity in size and density as seen by electron microscopy (",
"    <a class=\"graphic graphic_picture graphicRef74658 \" href=\"UTD.htm?3/28/3524\">",
"     picture 7",
"    </a>",
"    ). Peroxidase staining reveals both smaller peroxidase-negative granules (secondary specific granules, tertiary gelatinase granules) and larger dense peroxidase-positive granules (primary granules). The Golgi region of the PMN is small compared with the promyelocyte and myelocyte and is no longer forming granules; the rough endoplasmic reticulum and mitochondria are scant. PMN contain an abundance of glycogen, as the cell depends on anaerobic glycolysis for the generation of ATP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     REGULATION OF GRANULOCYTE DIFFERENTIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genomic studies using microarray technology have uncovered transcriptional gene expression patterns from highly enriched populations of myeloblasts, promyelocytes, myelocytes, metamyelocytes, band cells, and neutrophils from human bone marrow and neutrophils from peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/8\">",
"     8",
"    </a>",
"    ]. Gene expression was profiled employing over 44,000 probe sets including almost 11,000 probe sets for 6700 differentially regulated genes. These differentially regulated genes were assigned to four functional categories of cell cycle, apoptosis, receptors, and receptor ligands.",
"   </p>",
"   <p>",
"    Flow cytometry analysis demonstrated an abrupt decrease in proliferation at the promyelocyte to myelocyte transition coincident with a marked decrease in pro-proliferative genes, including E2F target genes and E2F-activity promoting kinases of the CDK family. The transcription factors of the",
"    <span class=\"nowrap\">",
"     C/EBP",
"    </span>",
"    family repress E2F-mediated transcription and remained expressed, suggesting a mechanism for cell cycle exit.",
"   </p>",
"   <p>",
"    Expression patterns for apoptosis-related genes indicated death control through the p53-dependent pathway in proliferating promyelocytes and through H1.2 death receptor pathways in bone marrow neutrophils.",
"   </p>",
"   <p>",
"    Effector proteins critical for host defense were expressed successively throughout granulocyte differentiation, whereas receptors and receptor ligands essential for the host defense program were terminally upregulated in bone marrow neutrophils. The upregulation of ligand-receptor pairs, which are defined inducers as well as target genes of nuclear factor-kB (NF-kB) suggests a constitutive activation of NF-kB in bone marrow neutrophils by autocrine loops.",
"   </p>",
"   <p>",
"    Overall, these results define a granulocyte differentiation model regulated by a highly coordinated program, allowing granulocyte differentiation before bone marrow neutrophils acquire responsiveness toward stimuli activated during inflammation or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CONTENT OF PMN GRANULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMN contain three subsets of granules (azurophilic, specific, and gelatinase) and one group of secretory vesicles identified by marker enzymes or other proteins present in the granule matrix or membranes of granules and vesicles (",
"    <a class=\"graphic graphic_table graphicRef57400 \" href=\"UTD.htm?41/7/42109\">",
"     table 1",
"    </a>",
"    ). Hepatocyte growth factor has been identified in specific and getatinase granules as well as in secretory vesicles of PMN.",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Azurophilic granules",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are myeloperoxidase-positive azurophil granules in promyelocytes and in all further differentiated stages of PMN. The matrix of azurophil granules contains microbicidal proteins and acid hydrolases involved in oxidative and nonoxidative killing of bacteria and fungi. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link\">",
"     \"Neutrophil functions other than movement\"",
"    </a>",
"    .) Azurophil granule membranes contain receptors and proteins for signal transduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Specific granules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactoferrin is localized to specific granules and serves as a convenient marker of these granules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. Specific granule matrix contains hydrolases distinct from those in the azurophil granules and vitamin B12 binding protein. Specific granule membranes contain chemotactic, opsonic and adhesion protein receptors and the cytochrome",
"    <span class=\"nowrap\">",
"     b/gp91",
"     <sup>",
"      phox",
"     </sup>",
"    </span>",
"    component of the phagocytic NADPH oxidase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Secretory vesicles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkaline phosphatase initially was thought to be a marker for specific granules, as it is present in myelocytes and all further stages of differentiated PMN [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Later studies showed that alkaline phosphatase is contained in secretory vesicles scattered throughout the cytoplasm and plasma membrane of myelocytes, metamyelocytes, band forms and PMN [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Gelatinase granules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another subset of specific-type granules has been identified by subcellular fractionation combined with double labeling immunoelectron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. These granules are rich in gelatinase but low in lactoferrin and do not contain myeloperoxidase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/19\">",
"     19",
"    </a>",
"    ]. Unless the granule is devoid of lactoferrin, it is considered part of the specific granule subset.",
"   </p>",
"   <p>",
"    Gelatinase granules are a marker of terminal neutrophil differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/13\">",
"     13",
"    </a>",
"    ]. They more readily secrete their contents in response to secretagogues than azurophilic or specific granules [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GRANULOCYTE KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMN are distributed within the bone marrow, the circulating blood, and in various tissues throughout the body depending upon specific need (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"UTD.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The bone marrow is the largest compartment; it contains approximately 2.3 x 10",
"      <sup>",
"       9",
"      </sup>",
"      PMN per kg body weight [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The peripheral blood compartment is one-third the size of the bone marrow compartment (0.7 x 10",
"      <sup>",
"       9",
"      </sup>",
"      cells per kg). One-half of these PMN is in the main stream of the circulation, while the other half is tumbling or loosely adhering to the endothelium of the microvasculature (",
"      <a class=\"graphic graphic_figure graphicRef78149 \" href=\"UTD.htm?18/63/19445\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/22\">",
"       22",
"      </a>",
"      ]. These two compartments are referred to as the circulating granulocyte pool (CGP) and marginating granulocyte pool (MGP), respectively; the two pools are in a constant state of dynamic equilibrium [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The size of the extravascular tissue compartment has not been quantified but it varies depending on the body's need for PMN at sites of infection or inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Bone marrow compartments",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three bone marrow compartments of developing myeloid precursors: the stem cell compartment, the mitotic compartment containing replicating myeloblasts, promyelocytes, and myelocytes, and the maturation-storage compartment containing nonreplicating maturing metamyelocytes, band forms and PMN. The size of the stem cell compartment has not been quantified but is very small compared with the mitotic compartment (2.1 x 10",
"    <sup>",
"     9",
"    </sup>",
"    cells per kg) and to the almost three-fold larger maturation-storage compartment (5.6 x 10",
"    <sup>",
"     9",
"    </sup>",
"    cells per kg) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/26\">",
"     26",
"    </a>",
"    ]. Studies in dogs suggest that rate of PMN production is approximately 1.7 x 10",
"    <sup>",
"     9",
"    </sup>",
"    per kg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/26\">",
"     26",
"    </a>",
"    ]. The factors regulating bone marrow PMN production are not well understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=see_link\">",
"     \"Regulation of myelopoiesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The transit times of developing myeloid cells have been derived from studies using tritiated thymidine [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. The entire process requires approximately 10 days under normal conditions (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"UTD.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ). The myeloblast stage is 15 hours, promyelocyte stage 24 hours, and myelocyte stage 104 hours, during which the myelocyte replicates up to three times. Thus, the replicating phase of myeloid development is about six days. Maturation of metamyelocyte to band form to PMN requires an additional four to five days. PMN may spend another three or four days in the storage compartment before emerging into the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Blood compartment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms controlling the release of PMN from the bone marrow are only partially understood. A variety of compounds induce PMN movement into the circulation including endotoxin, glucocorticoids, a leukocyte-mobilizing factor derived from the third component of complement (C3e), chemoattractants such as C5a, cytokines such as tumor necrosis factor (TNF)-alpha, and certain androgens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/30-34\">",
"     30-34",
"    </a>",
"    ]. To successfully emerge into the circulation, PMN must deform and migrate to the luminal side of the endothelial sinusoidal surface. Endotoxin affects the relationship between marrow sinus endothelial cells and the stromal macrophages covering nonluminal sinusoidal surfaces; it induces retraction of macrophages away from the endothelium which facilitates contact between PMN and endothelial cells and allows PMN egress from the bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In rabbits, infusion of C5a or TNF-alpha induces leukocytosis, which is not prevented when the principal adhesion proteins of PMN, beta-2 integrin and L-selectin, are blocked by specific antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/33\">",
"     33",
"    </a>",
"    ]. This observation suggests that PMN egress from the bone marrow is mediated by interactions different from those governing chemotaxis and diapedesis as described below (",
"    <a class=\"graphic graphic_figure graphicRef78149 \" href=\"UTD.htm?18/63/19445\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In early studies, when blood PMN were removed from the body, labeled, and reinjected, their measured half-life in the circulation was about seven hours [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/24,37\">",
"     24,37",
"    </a>",
"    ]. However, when labeled in vivo, the measured half-life in five normal volunteers was found to be considerably longer, at about 3.75 days (90 hours), for a mean lifespan of approximately 5.4 days (range: 5.1 to 8.4 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is now known that, in addition to its role in the regulation of granulopoiesis and maturation, G-CSF plays a significant role in reducing granulocyte transit time through the granulocyte compartment and releasing mature cells into the circulation. The CXC chemokine receptor 4 (CXCR4) also plays a significant role. It is expressed at high levels on early granulocytes and decreases with maturation to very low levels on mature granulocytes. The main ligand for CXCR4 is stromal-derived-factor-1 (SDF-1) and the interaction between these two proteins retains neutrophils in the marrow. This process also involves interaction with the",
"    <span class=\"nowrap\">",
"     &alpha;",
"     <sub>",
"      4",
"     </sub>",
"     /&beta;",
"     <sub>",
"      1",
"     </sub>",
"    </span>",
"    integrin VLA-4",
"    <span class=\"nowrap\">",
"     (CD49d/CD29),",
"    </span>",
"    which binds to VCMA1 and osteopontin, and crosstalk between the CXCR4-SDF-1 axis and VLA-4-VCAM-1 axis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/39\">",
"     39",
"    </a>",
"    ]. The loss of CXCR4 as neutrophils mature results in their release from the marrow. G-CSF can reduce expression of CXCR4 and cause release of granulocytes. As neutrophils become apoptotic in the circulation, CXCR4 is again expressed on the PMN surface and they return to the bone marrow where they are phagocytosed by stromal macrophages. This in turn stimulates G-CSF production, increasing production of neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disappearance of labeled PMN follows a single exponential curve, implying that PMN are destroyed or leave the blood randomly rather than according to their age (senescence) as is true for erythrocytes and platelets. PMN do not return to the circulation once they leave it. The granulocyte turnover rate is calculated from the total blood pool of PMN and is estimated at 0.3 to 1.3 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Circulating PMN interactions with endothelial cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMN are subjected to strong shear forces as blood flows through the arterial circulatory system at velocities of 300 to 1000",
"    <span class=\"nowrap\">",
"     &micro;m/sec",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/40\">",
"     40",
"    </a>",
"    ]. When viewing the microcirculation with the cine microscope, the vast majority of cells, including red cells, appear as an indistinguishable blur. But within this rapid flow, a subset of PMN is noted to tumble along the periphery of the blood vessel at a velocity about 100 times slower than the main flow. The loose selectin-mediated PMN interactions with the endothelium results in tumbling or rolling; it reflects early inflammatory responses of PMN and endothelial cells preceding firm adhesion of PMN to endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PMN recruitment to sites of inflammation involves a dynamic series of events between PMN and endothelial cells that are orchestrated by several different families of adhesion molecules and their ligands. Three families of adhesive molecules mediate the bulk of leukocyte-endothelial interactions (",
"    <a class=\"graphic graphic_table graphicRef57400 \" href=\"UTD.htm?41/7/42109\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Integrins &mdash; located on leukocytes",
"     </li>",
"     <li>",
"      Members of the immunoglobulin superfamily of proteins, primarily the intercellular adhesion molecules (ICAM) &mdash; largely expressed on endothelial cells",
"     </li>",
"     <li>",
"      Selectins &mdash; located on leukocytes and endothelial cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PMN and endothelial cells are transformed from a basal state to an activated state by a variety of inflammatory mediators. This process can be divided into the following phases (",
"    <a class=\"graphic graphic_figure graphicRef78149 \" href=\"UTD.htm?18/63/19445\">",
"     figure 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The inactivated or quiescent state of PMN and endothelium prior to the release of inflammatory mediators",
"     </li>",
"     <li>",
"      The activated state of endothelium (by factors such as IL-1, TNF-alpha, and endotoxin), leading to increased expression of adhesion molecules, particularly ICAM-1",
"     </li>",
"     <li>",
"      The activated or priming state of PMN, which is associated with alterations in the expression of adhesion molecules, making PMN sticky to the endothelium",
"     </li>",
"     <li>",
"      The transmigration phase when PMN tread between adjacent endothelial cells, supported by adhesion molecules expressed on the lateral surfaces of endothelium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rolling, which slows down PMN within the bloodstream, is primarily mediated by L-selectin on PMN and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/40,44,45\">",
"     40,44,45",
"    </a>",
"    ]. Adhesion to endothelial cells and migration between endothelial cells to extravascular sites requires activated neutrophils to shift expression from L-selectin to beta-2 integrin, primarily Mac-1",
"    <span class=\"nowrap\">",
"     (CD11b/CD18)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]; the beta-2 integrins mediate adhesion to ICAM-1 on the surface of inflamed endothelium (",
"    <a class=\"graphic graphic_figure graphicRef78149 \" href=\"UTD.htm?18/63/19445\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Extravascular tissue compartment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under normal conditions, PMN losses occur on mucosal surfaces throughout the body. As an example, isotopically labeled blood PMN appear in saliva and urine and increase markedly with inflammatory conditions such as gingivitis and pyelonephritis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. The exact size of the extravascular tissue compartment can only be estimated. Although PMN exit the circulation randomly, they age and die at inflammatory sites over the next 72 hours, in part by undergoing selective intracellular programmed cell death (apoptosis) and in part by recognition and engulfment by macrophages.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis results in characteristic morphologic changes in PMN volume and nuclear chromatin condensation called pyknocytosis. The apoptotic PMN remains intact morphologically but loses the cytoskeletal functions of attachment, spreading, shape change, and random migration. The expression of L-selectin decreases, Fc gamma RIIIb (CD16) is shed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/52\">",
"     52",
"    </a>",
"    ], but expression of the major adhesion protein Mac-1",
"    <span class=\"nowrap\">",
"     (CD11b/CD18)",
"    </span>",
"    increases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], and CXCR4 is again expressed on the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Apoptotic PMN cannot perform phagocytosis, degranulation, or respiratory burst activities [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, PMN apoptosis represents a modulating event in control of inflammation, marking PMN for disposal and minimizing their ability to generate and release noxious products that could induce further damage to inflamed tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The apoptotic PMN becomes the phagocytic target of tissue macrophages; it is recognized via adhesive proteins such as thrombospondin and ingested intact by the macrophage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/57\">",
"     57",
"    </a>",
"    ]. However, it is not clear if apoptosis is required for macrophage phagocytosis. The proto-oncogene B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (Bcl-2) is expressed in early myeloid differentiation but not in PMN. PMN from transgenic mice expressing Bcl-2 show delayed apoptosis in vitro but are still recognized and phagocytosed by macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise molecular genetic site(s) for initiation of apoptosis in PMN is not known. Sodium butyrate, which directly affects chromatin structure, delays PMN apoptosis, suggesting that active gene expression is involved [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/59\">",
"     59",
"    </a>",
"    ]. One candidate for a molecular trigger of apoptosis in PMN is the Fas (CD95) gene. Fas protein is expressed on the PMN plasma membrane and PMN constitutively release Fas ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/60\">",
"     60",
"    </a>",
"    ]. Since Fas ligand induces apoptosis in PMN, its release may provide a paracrine pathway for PMN to mediate programmed cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/60\">",
"     60",
"    </a>",
"    ]. As an example, high levels of circulating Fas ligand have been detected in patients with large granular lymphocyte leukemia, a disorder in which chronic neutropenia is a prominent feature [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=see_link&amp;anchor=H458740684#H458740684\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fas-mediated PMN apoptosis is suppressed in vitro by biologic molecules and drugs (eg, glucocorticoids) known to delay apoptosis in PMN. Molecules known to delay the onset of PMN apoptosis include G-CSF, GM-CSF, IL-3, IL-6, IL-15 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Glucocorticoids and G-CSF exert a protective effect on PMN survival in vitro at concentrations that correlate with pharmacologic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and G-CSF achievable in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Mediators of inflammation such as endotoxin, human recombinant C5a, TNF-alpha and interferon gamma also inhibit PMN apoptosis in a concentration dependent fashion in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/62\">",
"     62",
"    </a>",
"    ]. Lyn kinase, a src family tyrosine kinase, couples to the GM-CSF receptor and is required for the delayed apoptosis induced by GM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6185/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14873650\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14873754\">",
"    <span class=\"h2\">",
"     Maturational stages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The six stages of polymorphonuclear neutrophil (PMN) development are characterized by morphological criteria of developing myeloid cells, as seen by light microscopy. These criteria are: relative size, nuclear volume, chromatin density, prominence of nucleoli, granule number, and cytoplasmic staining. The stages are, as follows (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Morphology of developing neutrophils'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Myeloblast",
"     </li>",
"     <li>",
"      Promyelocyte",
"     </li>",
"     <li>",
"      Myelocyte",
"     </li>",
"     <li>",
"      Band form",
"     </li>",
"     <li>",
"      PMN (mature neutrophil)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The entire maturation process within the bone marrow requires approximately 10 days under normal conditions (myeloblast stage 15 hours, promyelocyte stage 24 hours, myelocyte stage 104 hours). Maturation of metamyelocyte to band form to PMN requires an additional four to five days. PMN may spend another three or four days in the bone marrow storage compartment before emerging into the circulation (",
"    <a class=\"graphic graphic_figure graphicRef75855 \" href=\"UTD.htm?30/58/31651\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Bone marrow compartments'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14873761\">",
"    <span class=\"h2\">",
"     PMN granules",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMN contain three subsets of granules (azurophilic, specific, and gelatinase) and one group of secretory vesicles identified by marker enzymes or other proteins present in the granule matrix or membranes of granules and vesicles (",
"    <a class=\"graphic graphic_table graphicRef57400 \" href=\"UTD.htm?41/7/42109\">",
"     table 1",
"    </a>",
"    ). The function of the various enzymes and proteins contained in these granules is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=see_link\">",
"     \"Neutrophil functions other than movement\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14873827\">",
"    <span class=\"h2\">",
"     PMN kinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;PMN are distributed within the bone marrow, the circulating blood, and in various tissues throughout the body depending upon specific need, as follows (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Granulocyte kinetics'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When blood PMN were labeled in vivo, the measured half-life in five normal volunteers was about 3.75 days, for a mean lifespan of approximately 5.4 days.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"       Granulocyte colony-stimulating factor",
"      </a>",
"      (G-CSF) and the chemokine receptor 4 (CXCR4) play a significant role in reducing granulocyte transit time through the granulocyte compartment and releasing mature cells into the circulation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Blood compartment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The disappearance of labeled PMN from the circulation follows a single exponential curve, implying that PMN are destroyed or leave the blood randomly rather than according to their age. PMN do not return to the circulation once they leave it.",
"     </li>",
"     <li>",
"      Although PMN exit the circulation randomly, they age and die at inflammatory sites over the next 72 hours, in part by undergoing selective intracellular programmed cell death (apoptosis) and in part by recognition and engulfment by macrophages. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Extravascular tissue compartment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Apoptosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Golde DW, Baldwin GC. Myeloid growth factors. In: Inflammation: Basic Principles and Clinical Correlates, 2nd ed, Gallin JI, Goldstein IM, Snyderman R (Eds), Raven Press, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/2\">",
"      Olweus J, Lund-Johansen F, Terstappen LW. CD64/Fc gamma RI is a granulo-monocytic lineage marker on CD34+ hematopoietic progenitor cells. Blood 1995; 85:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/3\">",
"      Leary AG, Ogawa M, Strauss LC, Civin CI. Single cell origin of multilineage colonies in culture. Evidence that differentiation of multipotent progenitors and restriction of proliferative potential of monopotent progenitors are stochastic processes. J Clin Invest 1984; 74:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/4\">",
"      Wognum AW, Westerman Y, Visser TP, Wagemaker G. Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets. Blood 1994; 84:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/5\">",
"      Sigurdsson F, Khanna-Gupta A, Lawson N, Berliner N. Control of late neutrophil-specific gene expression: insights into regulation of myeloid differentiation. Semin Hematol 1997; 34:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/6\">",
"      Kawamoto H, Ikawa T, Masuda K, et al. A map for lineage restriction of progenitors during hematopoiesis: the essence of the myeloid-based model. Immunol Rev 2010; 238:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/7\">",
"      Lian Z, Wang L, Yamaga S, et al. Genomic and proteomic analysis of the myeloid differentiation program. Blood 2001; 98:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/8\">",
"      Theilgaard-M&ouml;nch K, Jacobsen LC, Borup R, et al. The transcriptional program of terminal granulocytic differentiation. Blood 2005; 105:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/9\">",
"      Rosenbauer F, Tenen DG. Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 2007; 7:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/10\">",
"      Cramer E, Pryzwansky KB, Villeval JL, et al. Ultrastructural localization of lactoferrin and myeloperoxidase in human neutrophils by immunogold. Blood 1985; 65:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/11\">",
"      Borregaard N, Kjeldsen L, Lollike K, Sengel&oslash;v H. Granules and secretory vesicles of the human neutrophil. Clin Exp Immunol 1995; 101 Suppl 1:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/12\">",
"      Gullberg U, Andersson E, Garwicz D, et al. Biosynthesis, processing and sorting of neutrophil proteins: insight into neutrophil granule development. Eur J Haematol 1997; 58:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/13\">",
"      Borregaard N, Sehested M, Nielsen BS, et al. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood 1995; 85:812.",
"     </a>",
"    </li>",
"    <li>",
"     Bainton DF. Developmental biology of neutrophils and eosinophils. In: Inflammation Basic Principles and Clinical Correlates, 2nd ed, Raven Press, New York 1992. p.303.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/15\">",
"      DAVIDSON WM, SMITH DR. A morphological sex difference in the polymorphonuclear neutrophil leucocytes. Br Med J 1954; 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/16\">",
"      Grenier A, Chollet-Martin S, Crestani B, et al. Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils. Blood 2002; 99:2997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/17\">",
"      Kaplow LS. Cytochemistry of leukocyte alkaline phosphatase. Use of complex naphthol as phosphates in azo dyecoupling technics. Am J Clin Pathol 1963; 39:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/18\">",
"      KAPLOW LS. SIMPLIFIED MYELOPEROXIDASE STAIN USING BENZIDINE DIHYDROCHLORIDE. Blood 1965; 26:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/19\">",
"      Kjeldsen L, Bainton DF, Sengel&oslash;v H, Borregaard N. Structural and functional heterogeneity among peroxidase-negative granules in human neutrophils: identification of a distinct gelatinase-containing granule subset by combined immunocytochemistry and subcellular fractionation. Blood 1993; 82:3183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/20\">",
"      Dewald B, Bretz U, Baggiolini M. Release of gelatinase from a novel secretory compartment of human neutrophils. J Clin Invest 1982; 70:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/21\">",
"      ATHENS JW, RAAB SO, HAAB OP, et al. Leukokinetic studies. III. The distribution of granulocytes in the blood of normal subjects. J Clin Invest 1961; 40:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/22\">",
"      ATHENS JW, HAAB OP, RAAB SO, et al. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. J Clin Invest 1961; 40:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/23\">",
"      Boggs DR. The kinetics of neutrophilic leukocytes in health and in disease. Semin Hematol 1967; 4:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/24\">",
"      Mauer AM, Athens JW, Ashenbrucker H, et al. LEUKOKINETIC STUDIES. II. A METHOD FOR LABELING GRANULOCYTES IN VITRO WITH RADIOACTIVE DIISOPROPYLFLUOROPHOSPHATE (DFP). J Clin Invest 1960; 39:1481.",
"     </a>",
"    </li>",
"    <li>",
"     Bishop CR, Athens JW. Studies of granulocytopoiesis in abnormal conditions. In: Hemopoietic Cellular Proliferation, Stohlman F Jr (Ed), Grune &amp; Stratton, New York 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/26\">",
"      Deubelbeiss KA, Dancey JT, Harker LA, Finch CA. Neutrophil kinetics in the dog. J Clin Invest 1975; 55:833.",
"     </a>",
"    </li>",
"    <li>",
"     Cronkite EP, Vincent PC. Granulocytopoiesis. In: Hemopoietic Cellular Proliferation, Stohlman F Jr (Ed), Grune &amp; Stratton, New York 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/28\">",
"      Bishop CR, Rothstein G, Ashenbrucker HE, Athens JW. Leukokinetic studies. XIV. Blood neutrophil kinetics in chronic, steady-state neutropenia. J Clin Invest 1971; 50:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/29\">",
"      CARTWRIGHT GE, ATHENS JW, WINTROBE MM. THE KINETICS OF GRANULOPOIESIS IN NORMAL MAN. Blood 1964; 24:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/30\">",
"      Deinard AS, Page AR. A study of steroid-induced granulocytosis in a patient with chronic benign neutropenia of childhood. Br J Haematol 1974; 28:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/31\">",
"      Ghebrehiwet B, M&uuml;ller-Eberhard HJ. C3e: an acidic fragment of human C3 with leukocytosis-inducing activity. J Immunol 1979; 123:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/32\">",
"      Mitchell RH, McClelland RM, Kampschmidt RF. Comparison of neutrophilia induced by leukocytic endogenous mediator and by cobra venom factor. Proc Soc Exp Biol Med 1982; 169:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/33\">",
"      Jagels MA, Chambers JD, Arfors KE, Hugli TE. C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. Blood 1995; 85:2900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/34\">",
"      Vogel JM, Yankee RA, Kimball HR, et al. The effect of etiocholanolone on granulocyte kinetics. Blood 1967; 30:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/35\">",
"      Lichtman MA, Weed RI. Alteration of the cell periphery during granulocyte maturation: relationship to cell function. Blood 1972; 39:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/36\">",
"      Hirahata T, Bjorkman D, Chamberlain JK. Endotoxin: a twofold effect on bone marrow ultrastructure. Scanning Microsc 1987; 1:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/37\">",
"      ATHENS JW, HAAB OP, RAAB SO, et al. LEUKOKINETIC STUDIES. XI. BLOOD GRANULOCYTE KINETICS IN POLYCYTHEMIA VERA, INFECTION, AND MYELOFIBROSIS. J Clin Invest 1965; 44:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/38\">",
"      Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood 2010; 116:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/39\">",
"      Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol 2010; 31:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/40\">",
"      Kishimoto TK, Rothlein R. Integrins, ICAMs, and selectins: role and regulation of adhesion molecules in neutrophil recruitment to inflammatory sites. Adv Pharmacol 1994; 25:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/41\">",
"      Varki A. Selectin ligands. Proc Natl Acad Sci U S A 1994; 91:7390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/42\">",
"      Cronstein BN, Weissmann G. The adhesion molecules of inflammation. Arthritis Rheum 1993; 36:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/43\">",
"      McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/44\">",
"      Smith CW, Rothlein R, Hughes BJ, et al. Recognition of an endothelial determinant for CD 18-dependent human neutrophil adherence and transendothelial migration. J Clin Invest 1988; 82:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/45\">",
"      Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell 1991; 65:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/46\">",
"      Springer TA, Thompson WS, Miller LJ, et al. Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis. J Exp Med 1984; 160:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/47\">",
"      Gotsch U, J&auml;ger U, Dominis M, Vestweber D. Expression of P-selectin on endothelial cells is upregulated by LPS and TNF-alpha in vivo. Cell Adhes Commun 1994; 2:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/48\">",
"      Dustin ML, Rothlein R, Bhan AK, et al. Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/49\">",
"      Hibbs ML, Xu H, Stacker SA, Springer TA. Regulation of adhesion of ICAM-1 by the cytoplasmic domain of LFA-1 integrin beta subunit. Science 1991; 251:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/50\">",
"      GARNETT ES. OBSERVATIONS ON THE KINETICS OF URINARY GRANULOCYTE EXCRETION. Clin Sci 1965; 28:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/51\">",
"      FLIEDNER TM, CRONKITE EP, ROBERTSON JS. GRANULOCYTOPOIESIS. I. SENESCENCE AND RANDOM LOSS OF NEUTROPHILIC GRANULOCYTES IN HUMAN BEINGS. Blood 1964; 24:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/52\">",
"      Dransfield I, Buckle AM, Savill JS, et al. Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol 1994; 153:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/53\">",
"      Coxon A, Rieu P, Barkalow FJ, et al. A novel role for the beta 2 integrin CD11b/CD18 in neutrophil apoptosis: a homeostatic mechanism in inflammation. Immunity 1996; 5:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/54\">",
"      Walzog B, Jeblonski F, Zakrzewicz A, Gaehtgens P. Beta2 integrins (CD11/CD18) promote apoptosis of human neutrophils. FASEB J 1997; 11:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/55\">",
"      Whyte MK, Meagher LC, MacDermot J, Haslett C. Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 1993; 150:5124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/56\">",
"      Savill JS, Wyllie AH, Henson JE, et al. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 1989; 83:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/57\">",
"      Savill J, Hogg N, Ren Y, Haslett C. Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 1992; 90:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/58\">",
"      Lagasse E, Weissman IL. bcl-2 inhibits apoptosis of neutrophils but not their engulfment by macrophages. J Exp Med 1994; 179:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/59\">",
"      Stringer RE, Hart CA, Edwards SW. Sodium butyrate delays neutrophil apoptosis: role of protein biosynthesis in neutrophil survival. Br J Haematol 1996; 92:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/60\">",
"      Liles WC, Kiener PA, Ledbetter JA, et al. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/61\">",
"      Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by fas ligand. Blood 2000; 95:3219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/62\">",
"      Lee A, Whyte MK, Haslett C. Inhibition of apoptosis and prolongation of neutrophil functional longevity by inflammatory mediators. J Leukoc Biol 1993; 54:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/63\">",
"      Maianski NA, Mul FP, van Buul JD, et al. Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood 2002; 99:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/64\">",
"      Basu S, Hodgson G, Katz M, Dunn AR. Evaluation of role of G-CSF in the production, survival, and release of neutrophils from bone marrow into circulation. Blood 2002; 100:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/65\">",
"      Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995; 154:4719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/66\">",
"      Liles WC, Dale DC, Klebanoff SJ. Glucocorticoids inhibit apoptosis of human neutrophils. Blood 1995; 86:3181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6185/abstract/67\">",
"      Wei S, Liu JH, Epling-Burnette PK, et al. Critical role of Lyn kinase in inhibition of neutrophil apoptosis by granulocyte-macrophage colony-stimulating factor. J Immunol 1996; 157:5155.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8378 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6185=[""].join("\n");
var outline_f6_2_6185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14873650\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MORPHOLOGY OF DEVELOPING NEUTROPHILS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Myeloblast stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Promyelocyte stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myelocyte stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metamyelocyte stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Band form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Polymorphonuclear neutrophil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      REGULATION OF GRANULOCYTE DIFFERENTIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CONTENT OF PMN GRANULES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Azurophilic granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Specific granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Secretory vesicles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Gelatinase granules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GRANULOCYTE KINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Bone marrow compartments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Blood compartment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Circulating PMN interactions with endothelial cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Extravascular tissue compartment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14873650\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14873754\">",
"      Maturational stages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14873761\">",
"      PMN granules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14873827\">",
"      PMN kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/8378\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8378|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?34/9/34968\" title=\"algorithm 1\">",
"      Hematopoiesis regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8378|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/58/31651\" title=\"figure 1\">",
"      PMN development and kinetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/63/19445\" title=\"figure 2\">",
"      Neutrophil migration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8378|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/11/38067\" title=\"picture 1\">",
"      Normal human myeloblast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/25/21908\" title=\"picture 2\">",
"      Normal human promyelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/7/1138\" title=\"picture 3\">",
"      Normal human myelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/60/26563\" title=\"picture 4\">",
"      Normal human metamyelocyte",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/42/17060\" title=\"picture 5\">",
"      Normal human band form",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/37/31316\" title=\"picture 6\">",
"      Normal human PMN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/28/3524\" title=\"picture 7\">",
"      Normal resting PMN EM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/8378|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/7/42109\" title=\"table 1\">",
"      PMN granule contents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?12/1/12305?source=related_link\" title=\"calculator 1\">",
"      Calculator: Absolute neutrophil count",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21018?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell large granular lymphocyte leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/31/6650?source=related_link\">",
"      Neutrophil functions other than movement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6858?source=related_link\">",
"      Regulation of myelopoiesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_2_6186="Hepatitis C virus infection in children";
var content_f6_2_6186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatitis C virus infection in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/2/6186/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6186/contributors\">",
"     Maureen M Jonas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/2/6186/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6186/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6186/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/2/6186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/2/6186/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/2/6186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children represent only a small proportion of the hepatitis C virus (HCV)-infected population. Nevertheless, a substantial number of children have chronic HCV infection and are at risk for complications.",
"   </p>",
"   <p>",
"    The major issues related to HCV in children will be reviewed here. Perinatal transmission of HCV is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, antibodies to HCV are present in approximately 0.2 percent of children ages 6 to 12 and in 0.4 percent of those ages 12 to 19, rates that are similar to the prevalence observed in volunteer adult blood donors but that are lower than adult prevalence based upon National Health and Nutrition Examination survey data [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The prevalence rate in children is based upon screening tests performed on a nationally representative sample [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/1\">",
"     1",
"    </a>",
"    ]. In comparison, the frequency of cases that are clinically identified is far lower (5 percent of the expected number), suggesting that screening for and case identification of pediatric HCV are grossly inadequate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/4\">",
"     4",
"    </a>",
"    ]. The proportion of children who are HCV antibody-positive who are also HCV RNA positive is not known precisely; based upon studies in adults, it is estimated to be approximately 75 to 80 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence is much higher (50 to 95 percent) in individuals who received blood products for conditions such as thalassemia or hemophilia before 1990 (when a first-generation ELISA test became available and routine screening of the blood supply began) to as late as 1992 (when the second-generation ELISA test was introduced) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Seroprevalence rates of 10 to 20 percent have been reported among children with a variety of other potential exposures such as malignancy, hemodialysis, extracorporeal membrane oxygenation, or surgery for congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]. A 2 percent seroprevalence rate was found in an incarcerated juvenile population in Washington, DC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/14\">",
"     14",
"    </a>",
"    ]. As a general rule, the risk of HCV infection in children who were exposed to blood products before routine screening is related to the number of units of blood or blood products received [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/10,12,15\">",
"     10,12,15",
"    </a>",
"    ]. Most of these at-risk children are now young adults, as routine testing of the blood supply has virtually eliminated transmission via this route.",
"   </p>",
"   <p>",
"    There appears to be worldwide geographic variation in the prevalence of HCV infection in children, the reasons for which are incompletely understood. Studies in the early 1990s (which reflected populations of children who could have been exposed to contaminated blood products) reported prevalence rates ranging from 0 percent in Japan and Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]; 0.4 percent in Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/18\">",
"     18",
"    </a>",
"    ]; 0.6 percent in Malaysia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/19\">",
"     19",
"    </a>",
"    ]; 0.9 percent in Saudi Arabia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/20\">",
"     20",
"    </a>",
"    ]; 1.4 percent in Moldova [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/21\">",
"     21",
"    </a>",
"    ]; and up to 14.5 percent in Cameroon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/22\">",
"     22",
"    </a>",
"    ]. Prevalence rates in Egypt were low in the 1990s among children without a history of exposure to blood products [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/15\">",
"     15",
"    </a>",
"    ], but a more recent series reported HCV rates of 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Overall, approximately 28,000 new HCV infections occur in the United States each year, although the specific incidence in children is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/24\">",
"     24",
"    </a>",
"    ]. Perinatal transmission is by far the most common source of infection in children, accounting for about 750 new",
"    <span class=\"nowrap\">",
"     cases/year",
"    </span>",
"    in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/2\">",
"     2",
"    </a>",
"    ]. Adolescents may be exposed through high-risk behaviors such as intravenous or intranasal drug use and use of shared tattoo equipment. The incidence of HCV vertical transmission is approximately 2 to 5 percent in HCV RNA positive mothers, with the highest risk in mothers with high HCV viral load. The risk also is increased at least fourfold for mothers with HIV coinfection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology of HCV infection in developed countries is changing. As an example, the prevalence of HCV infection among Italian children dropped by more than 40 percent in the late 1990s, and all new cases appeared to reflect perinatal transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/25\">",
"     25",
"    </a>",
"    ]. Some of this change is attributable to elimination of transfusion-associated hepatitis because of donor screening programs. In addition, several factors may have contributed to reductions in vertical transmission observed in some populations. One such factor is that fewer women of childbearing age are infected with HCV due to prevention campaigns; other factors include aging of women infected by transfusions and changing patterns of drug abuse. In addition, antiretroviral therapy in",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    co-infected women and effective treatment of HCV reduces the rate of vertical transmission by HCV infected women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of HCV in children is incompletely understood. Because the disease generally progresses slowly, serious consequences such as cirrhosis or hepatocellular carcinoma are rare during childhood. The following general observations have emerged from natural history studies in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Spontaneous clearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections acquired during infancy (either by transfusion or through perinatal transmission) are more likely to resolve spontaneously than infections acquired later in life. Spontaneous clearance rates ranging from 20 to 45 percent have been described in such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/2,26-32\">",
"     2,26-32",
"    </a>",
"    ]. Infants with vertically transmitted HCV have rates of clearance on the lower end of this range. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Factors associated with disease progression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One of the largest series with long-term follow-up in perinatally acquired HCV included 266 children who were followed for a median of 4.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/33\">",
"     33",
"    </a>",
"    ]. Approximately 20 percent cleared the infection while 80 percent had chronic infection. Clearance was less likely in children who remained polymerase chain reaction (PCR)-positive after the first year of life and those who were persistently PCR positive during the first year of life. Most children with chronic infection were asymptomatic. Hepatomegaly was observed in 10 percent.",
"   </p>",
"   <p>",
"    There is also some evidence that the risk of developing chronic infection may be lower in patients presenting with symptomatic acute HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link&amp;anchor=H164590471#H164590471\">",
"     \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\", section on 'Spontaneous viral clearance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many patients, fibrosis scores tend to increase with age, suggesting there is slowly progressive histologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/35-38\">",
"     35-38",
"    </a>",
"    ]. The development of advanced liver disease is uncommon until more than 30 years after infection in children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, progression to advanced fibrosis and cirrhosis during childhood has been reported, as described in the following case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 121 treatment-naive children with hepatitis C, 80 percent had some fibrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/38\">",
"       38",
"      </a>",
"      ]. This was usually mild, but five patients had bridging fibrosis, and two had cirrhosis. The patients with advanced fibrosis tended to be older, suggesting that fibrosis increases with time. Obesity and perhaps other cofactors probably contribute to the severity of the liver disease.",
"     </li>",
"     <li>",
"      In a series of 332 children with hepatitis C and persistent viremia, six children progressed to decompensated cirrhosis; the duration of infection before cirrhosis noted was 2 to 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/39\">",
"       39",
"      </a>",
"      ]. Five of the six children were infected with genotype 1a HCV, and only one was co-infected with HIV.",
"     </li>",
"     <li>",
"      In our practice, we have seen three children who developed decompensated cirrhosis at ages 11, 13, and 16, respectively. Three children with decompensated HCV-associated cirrhosis at ages 4, 6, and 11 years also have been reported by other centers [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/40\">",
"       40",
"      </a>",
"      ]. In all of these children the HCV infection was acquired perinatally.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Factors associated with disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors associated with disease progression have been described, although the strength of these associations is unclear. Clinical predictors for disease progression in adults are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Reason for transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have suggested that the natural history of HCV among children infected via transfusion depends upon the underlying disease for which transfusion was required [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/13,28,29,32\">",
"     13,28,29,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital heart disease &mdash; Spontaneous clearance appears to occur relatively commonly (45 to 55 percent) in children who received a blood transfusion during surgery for congenital heart disease. Furthermore, severe histologic injury in such patients appears to be uncommon [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/13,29,32\">",
"       13,29,32",
"      </a>",
"      ]. Despite this somewhat improved prognosis compared to other groups infected with HCV, these individuals are at risk for significant disease and should be treated accordingly. The risk for HCV infection after cardiac surgery has dropped to less than 0.5 percent in some areas, underscoring the effectiveness of blood donor screening programs [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thalassemia &mdash; End-stage liver disease during childhood is uncommon in children who received transfusions for thalassemia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/6\">",
"       6",
"      </a>",
"      ]. However, such patients are at risk for liver injury from secondary hemochromatosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/42\">",
"       42",
"      </a>",
"      ]. Iron overload also may diminish the response to therapy for HCV [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hemophilia &mdash; HCV infection may contribute to morbidity and mortality in children with hemophilia, although end-stage liver disease is uncommon before adulthood [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Leukemia &mdash; Children treated for leukemia before 1990 have a high rate of HCV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/46\">",
"       46",
"      </a>",
"      ]. In one report, serious liver disease did not develop after 13 to 27 years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/47\">",
"       47",
"      </a>",
"      ]. On the other hand, another study of 77 HCV-infected children who had been treated for cancer found one death from liver disease and two deaths from hepatocellular carcinoma in the decades following HCV acquisition [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/48\">",
"       48",
"      </a>",
"      ]. In addition, 9 percent of patients developed cirrhosis 9 to 27 years after diagnosis of the primary malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Perinatal transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatally acquired HCV infection has become the major route of new infections in children in developed countries. Such children commonly have elevated serum aminotransferases for a few years that often become normal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/49\">",
"     49",
"    </a>",
"    ]. Ten to 20 percent of children with vertically transmitted HCV infection clear the virus during the first two years of life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/30,33\">",
"     30,33",
"    </a>",
"    ]. Estimated rates of spontaneous clearance vary, probably because different standards are used to define the infected status at birth; one small series suggested spontaneous clearance rates of up to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/50\">",
"     50",
"    </a>",
"    ]. Almost all children who remain viremic thereafter have chronic hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/30,33,51,52\">",
"     30,33,51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other factors associated with disease progression have been identified including immunosuppression (from HIV infection or other causes), chronic alcohol ingestion, and obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;How to identify children at risk for having HCV is uncertain. A review of 1034 children seen in an urban pediatric hospital found only one who was HCV positive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/54\">",
"     54",
"    </a>",
"    ]. A history of blood transfusion was reported by 7 percent of mothers and intravenous drug use by 1.8 percent. Mothers tended to underreport prior use of intravenous drugs compared with a review of their medical records. Based upon such observations, most experts think that universal screening of children for HCV in high-risk urban communities is not warranted.",
"   </p>",
"   <p>",
"    We suggest that the following groups be screened for HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with clinical evidence of hepatitis, including unexplained elevation of serum alanine aminotransferase (ALT)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aspartate aminotransferase (AST), even if asymptomatic",
"     </li>",
"     <li>",
"      Children whose mothers are known to be infected with HCV or have a history of intravenous drug use. For these infants, testing for HCV antibodies should be performed after 18 months of age, because the results of this test in younger infants may reflect passive transfer of maternal antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/55\">",
"       55",
"      </a>",
"      ]. If earlier diagnosis is desired, testing for HCV RNA may be performed at four months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children who are international adoptees or refugees, because most children adopted into the United States in recent years have come from countries with relatively high prevalence rates, including Africa, China, Russia, Eastern Europe and Southeast Asia, and because risk factors for infection rarely are known [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children and adolescents with HIV infection",
"     </li>",
"     <li>",
"      Adolescents or children who are victims of a sexual assault, or adolescents with a history of multiple sexual partners",
"     </li>",
"     <li>",
"      Adolescents with a history of drug use",
"     </li>",
"     <li>",
"      Individuals who received blood products before 1992",
"     </li>",
"     <li>",
"      Individuals with a history of care in a neonatal intensive care unit (NICU) prior to 1992, whether or not they are aware of a history of blood transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individuals who received blood transfusions during infancy in neonatal intensive care units (NICU) prior to 1992 are at risk for HCV infection and represent a large risk group (approximately 500,000 in the United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/58\">",
"     58",
"    </a>",
"    ]. These individuals are now young adults. A study of children who had received blood transfusions as in a NICU revealed that 3 percent had previously unrecognized HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/59\">",
"     59",
"    </a>",
"    ]. Only half of the patients or families were aware that they had received the blood transfusion during the neonatal period. It is unclear whether systematic screening programs for NICU graduates are a practicable or cost-effective approach to identifying new cases of HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of diagnosis of HCV infection in children are similar to those employed in adults. Issues related to diagnosis in the perinatal period are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;When HCV infection is diagnosed in a child, further evaluation is warranted to inform treatment decisions and to monitor for progression of liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     HCV genotyping",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCV genotyping is useful for guiding the duration of therapy and predicting the likelihood of response. As a result, we recommend HCV genotyping for children with confirmed HCV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A liver biopsy is not required to establish the diagnosis of HCV infection. However, liver histology (particularly the degree of fibrosis) is useful for predicting the prognosis of the disease, and may therefore inform treatment decisions (",
"    <a class=\"graphic graphic_algorithm graphicRef72599 \" href=\"UTD.htm?31/50/32558\">",
"     algorithm 1",
"    </a>",
"    ). In our practice, most decisions about liver biopsies fall into one of the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For children with HCV genotype 1 who are older than five years of age, we offer a liver biopsy if the family is unsure about whether to proceed to treatment. This is because patients with this genotype 1 are less likely to respond to treatment, and the biopsy may provide prognostic information that will help with the treatment decision. We typically recommend a liver biopsy for prognostic purposes in children older than 10 years of age, or if there is comorbid disease or other features that raise concern for rapid progression.",
"     </li>",
"     <li>",
"      For children with genotype 2 or 3, we do not generally perform liver biopsies. These children are very likely to respond to combination treatment, and we would recommend treatment regardless of the stage of liver disease. We do offer a liver biopsy if the parents want to know the stage of disease in considering treatment, or if the child has comorbid disease for which the results of a biopsy might influence the decision to treat.",
"     </li>",
"     <li>",
"      For a child with genotype 1 and HCV recently acquired through horizontal transmission (eg, infection from intravenous drug use), liver biopsy may not be necessary. Such individuals are unlikely to have advanced liver disease within a few years of acquisition; thus, biopsy results are unlikely to influence the treatment decision. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Decision to treat'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic features of HCV infection in children are similar to those in adults. Characteristic findings include portal lymphoid aggregates or follicles, steatosis, sinusoidal lymphocytes, and steatosis (",
"    <a class=\"graphic graphic_picture graphicRef69510 \" href=\"UTD.htm?11/63/12279\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/36,37,60\">",
"     36,37,60",
"    </a>",
"    ]. Although the histologic features are similar, liver disease appears to be less severe in children than in adults with similar duration of infection, HCV-RNA level, and genotype (",
"    <a class=\"graphic graphic_picture graphicRef53561 \" href=\"UTD.htm?33/0/33799\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/61\">",
"     61",
"    </a>",
"    ]. Cirrhosis is less common than in adults, but may occur during childhood or adolescence (",
"    <a class=\"graphic graphic_picture graphicRef73535 \" href=\"UTD.htm?21/25/21910\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Natural history'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The best clinical predictors of disease progression in adults with chronic HCV infection are the amount of inflammation and fibrosis on liver biopsy. Other clinical factors that predict disease progression are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\", section on 'Liver biopsy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6\">",
"     'Factors associated with disease progression'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serum aminotransferases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum aminotransferase levels are not consistently related to disease severity in HCV-infected patients. In one series of children with HCV infection, one-third had normal aminotransferase levels, despite substantial histopathological evidence of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/38\">",
"     38",
"    </a>",
"    ]. However, serial measurements may be used to monitor disease activity.",
"   </p>",
"   <p>",
"    In our practice, we monitor otherwise healthy HCV-infected children by physical examination and measurement of alanine aminotransferase every 6 to 12 months. More frequent monitoring is performed in children with comorbidities, such as coinfection with HIV, or those taking potentially hepatotoxic medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic infection with HCV has been associated with hepatocellular carcinoma (HCC), which occurs almost exclusively in individuals with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/62\">",
"     62",
"    </a>",
"    ]. As a result, HCC is rare among children infected with HCV, but appears to be more common in children who developed HCV after treatment for childhood leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/48,62\">",
"     48,62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, we monitor children for the possibility of HCC only in patients with advanced cirrhosis or other risk factors for HCC, including coinfection with hepatitis B virus (which can cause HCC in the absence of cirrhosis) or a coexisting malignancy. In such patients, we perform liver ultrasonography and measure serum alpha fetoprotein levels annually. Successful treatment of HCV in cirrhotic patients probably does not eliminate the risk of HCC, so we continue to monitor these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Hepatitis C'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Acute infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute HCV infection is uncommonly recognized in children except in rare outbreaks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/34\">",
"     34",
"    </a>",
"    ]. Fulminant hepatitis is rare. There are no data regarding treatment of acute HCV infection in children. We generally observe such patients for six to eight weeks to determine whether there is spontaneous clearance, treating those who continue to have HCV viremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chronic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of HCV in children was initially guided by experience in adults, but now includes multicenter trials in pediatric populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Pegylated interferon plus ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pegylated interferon, in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    , is the treatment of choice for most adults and children with chronic HCV infection who are considered to be appropriate candidates for therapy.",
"   </p>",
"   <p>",
"    In adults, response rates are higher among patients treated with combination therapy using pegylated interferon as compared to those treated combination therapy using standard interferon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Published data on this treatment in children are limited to small studies, as illustrated by the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open-labeled, uncontrolled pilot study, 62 children and adolescents, 2 to 17 years of age (mean 10.6 years), with chronic HCV were treated with subcutaneous",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38088?source=see_link\">",
"       pegylated interferon alfa-2b",
"      </a>",
"      and oral",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"       ribavirin",
"      </a>",
"      for 48 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/63\">",
"       63",
"      </a>",
"      ]. The SVR rate in this cohort was 59 percent at 18 months.",
"     </li>",
"     <li>",
"      A multicenter trial in 114 children with chronic HCV studied the combination of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=see_link\">",
"       pegylated interferon alfa-2a",
"      </a>",
"      (180",
"      <span class=\"nowrap\">",
"       micrograms/1.73",
"      </span>",
"      <span class=\"nowrap\">",
"       m",
"       <sup>",
"        2",
"       </sup>",
"       /week)",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"       ribavirin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      orally) as compared to pegylated interferon and placebo (PEDS-C trial) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/64\">",
"       64",
"      </a>",
"      ]. The SVR rate was substantially higher in children receiving combination therapy (53 percent) than in those receiving pegylated interferon without ribavirin (21 percent). Combination therapy was also more effective than peginterferon plus placebo in both the subgroup with genotype 1 (SVR 47 percent versus 18 percent) and in the subgroup with non-1 genotypes (SVR 80 percent versus 36 percent).",
"     </li>",
"     <li>",
"      A multicenter trial in 107 children with chronic HCV evaluated the efficacy and safety of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38088?source=see_link\">",
"       pegylated interferon alfa-2b",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       micrograms/m",
"       <sup>",
"        2",
"       </sup>",
"       /week)",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"       ribavirin",
"      </a>",
"      (15",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      orally) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/65\">",
"       65",
"      </a>",
"      ]. Children with genotype 2 or 3 with a low viral load (&lt;600,000",
"      <span class=\"nowrap\">",
"       IU/mL)",
"      </span>",
"      were treated for 24 weeks, and those with genotype 1 or 4, or genotype 3 with a high viral load, were treated for 48 weeks. The SVR was 93 percent in patients with genotype 2 or 3, and 53 percent in those with genotype 1. Adverse effects included anxiety, depression, or irritability in 28 percent (most did not require antidepressant treatment), and anemia, neutropenia, or weight loss requiring dose reduction in 25 percent.",
"     </li>",
"     <li>",
"      An international multicenter trial of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=see_link\">",
"       pegylated interferon alfa-2a",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       micrograms/m",
"       <sup>",
"        2",
"       </sup>",
"       /week)",
"      </span>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"       ribavirin",
"      </a>",
"      achieved very similar results [",
"      <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/66\">",
"       66",
"      </a>",
"      ]. Among 18 children with genotypes 2 and 3 (group A), who were treated for 24 weeks, the SVR was 89 percent. Among 47 children with genotypes 1, 4, 5 or 6 (group B), who were treated with combination therapy for 48 weeks, the SVR was 57 percent. Ten patients in group B stopped treatment prematurely: eight patients because of lack of response, and two because of serious adverse events (acute hepatitis or thyrotoxicosis). &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In 2008, the US Food and Drug administration (FDA) approved combination therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38088?source=see_link\">",
"     pegylated interferon alfa-2b",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    for use in children with HCV three years and older with compensated liver disease. This decision was supported by the results of the large trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/65\">",
"     65",
"    </a>",
"    ]. In 2011,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    was approved for use with ribavirin in children in the United States.",
"   </p>",
"   <p>",
"    The adverse effects of pegylated interferon are similar to those of standard interferon, and include pyrexia, headache, gastrointestinal symptoms and depression. Pegylated interferon is associated with weight loss or reduced weight gain, slowed linear growth, and decreased body mass index during the course of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/67\">",
"     67",
"    </a>",
"    ]. These effects generally reverse after cessation of therapy, but residual effects on height may be seen almost two years after the end of treatment. Overall quality of life and psychosocial functioning are not significantly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/68\">",
"     68",
"    </a>",
"    ]. Retinopathy or uveitis develops in 2 to 3 percent of patients treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=see_link\">",
"     pegylated interferon alfa-2a",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/69\">",
"     69",
"    </a>",
"    ]. Therefore, we perform a baseline ophthalmologic examination prior to treatment, and repeat the examination during treatment if symptoms develop. Neutropenia may be significant, but infections associated with the neutropenia are rare. Important adverse effects of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    include hemolytic anemia and teratogenicity. These adverse effects are similar to those seen in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2009, it was discovered that single nucleotide polymorphisms located near the gene for interleukin-28B (IL28B) were strongly associated with likelihood of achieving SVR with peginterferon and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    treatment. A particular polymorphism on chromosome 19, rs12979860, was found to be strongly associated with SVR in a number of different adult patient groups [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/70\">",
"     70",
"    </a>",
"    ]. It has become clear from numerous subsequent studies that host",
"    <em>",
"     IL28B",
"    </em>",
"    genotype has a profound effect on outcome of treatment, and this factor will be incorporated into future therapeutic trials and perhaps even into the routine management of HCV-infected patients. Testing for",
"    <em>",
"     IL28B",
"    </em>",
"    genotype has become more widely available, and could be considered when making treatment decisions regarding likelihood of response and duration of therapy. However,",
"    <em>",
"     IL28B",
"    </em>",
"    genotype has not yet been evaluated as a predictor of response in the pediatric population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Standard interferon plus ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with interferon-alfa and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    was the first established treatment for HCV infection in children [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/71\">",
"     71",
"    </a>",
"    ]. For most children and adults, pegylated interferon is now preferred. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Pegylated interferon plus ribavirin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Interferon monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early studies, interferon monotherapy (interferon without",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) in children with HCV produced rates of sustained virologic response (SVR) ranging from 33 to 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/72\">",
"     72",
"    </a>",
"    ]. The SVR rate appeared to be higher in children than in adults. Nonetheless, interferon monotherapy is not recommended because it has substantially lower SVR rates than combination therapy, as discussed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22932936\">",
"    <span class=\"h3\">",
"     Triple therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of May 2011, two protease inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    , are licensed in the United States for use in combination with pegylated interferon and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    in adults with chronic HCV genotype 1. This therapy is associated with a significantly higher rate of sustained virologic response as compared with the combination of pegylated interferon and ribavirin. A pediatric trial of combination therapy with boceprevir is underway (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT01590225\">",
"     NCT01590225",
"    </a>",
"    ), and a trial of telaprevir is being planned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Decision to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practice recommendations for children with chronic HCV are similar to those for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/55\">",
"     55",
"    </a>",
"    ]. However, because of limited data in the pediatric age group, treatment decisions may vary with the child's age and individual disease characteristics. The following recommendations reflect our practice and are based on the pediatric studies cited above, as well some extrapolations from adult treatment trials.",
"   </p>",
"   <p>",
"    Combination treatment with peginterferon plus",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    should be considered for children with chronic HCV infection who are older than three years and who appear to have progressive disease or advanced histologic features. For these children, our course of action depends on the HCV genotype (",
"    <a class=\"graphic graphic_algorithm graphicRef72599 \" href=\"UTD.htm?31/50/32558\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For those with genotype 2 or 3 (in whom response rates are highest), we proceed to treatment. We do not generally recommend a liver biopsy before treatment in such patients since the response rates are high. Exceptions are children whose parents want to know the stage of disease in considering treatment, and those with comorbid diseases in whom the results of a biopsy might influence the decision to treat.",
"     </li>",
"     <li>",
"      For those with genotype 1, we also encourage proceeding to treatment, but the child's age, presence of comorbid diseases, and family's preference are important components of the decision (",
"      <a class=\"graphic graphic_algorithm graphicRef72599 \" href=\"UTD.htm?31/50/32558\">",
"       algorithm 1",
"      </a>",
"      ). We encourage treatment more strongly in children with perinatally acquired HCV who are older than 10 years, and in those with a comorbid disease or other features that raise concern for rapid progression; for these groups we recommend a liver biopsy primarily for prognostic purposes rather than as part of a treatment decision (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Liver biopsy'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For younger patients with genotype 1 (between 3 and 10 years old), some families would like to have additional prognostic information prior to making a treatment decision, because these patients are less likely to respond to treatment than those with genotypes 2 or 3. In this case, we recommend a liver biopsy to assist in the treatment decision (unless there are contraindications such as hemophilia, or unless the HCV was clearly recently acquired). When a liver biopsy is performed, our treatment recommendation depends on the results. For patients with moderate or severe histopathology we recommend treatment, on the presumption that this finding indicates more rapid disease progression. For those with mild histopathologic features, we encourage treatment, but recognize that it is reasonable to observe without treatment; we make this decision with the family after consideration of the efficacy of treatment for this group and the potential risks for the individual patient. If observation is chosen, we suggest reevaluation with a liver biopsy in five to seven years.",
"   </p>",
"   <p>",
"    For patients with genotype 1 who are close to 18 years of age, we may recommend waiting until after the 18",
"    <sup>",
"     th",
"    </sup>",
"    birthday, then treating with the regimen recommended for adults, which now includes the protease inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H22932936\">",
"     'Triple therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Patients with obesity are also somewhat less likely to respond to HCV therapy. In one study using several different IFN-based treatments, each standard deviation (1 Z-score unit) increase in Body Mass Index was associated with a 12 percent decrease in the probability of a sustained virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/53\">",
"     53",
"    </a>",
"    ]. However, because of limited evidence we do not exclude overweight or obese children from consideration of treatment. On the other hand, since progression of liver injury from HCV is slow, for obese children we often encourage a period of weight loss for several months or a year before initiating antiviral therapy. The association between obesity and reduced treatment response has also been observed in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=see_link&amp;anchor=H16092975#H16092975\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'Other predictors'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     How to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;When treatment is chosen for any of the above groups, we recommend the combination of pegylated interferon with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/55\">",
"     55",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38088?source=see_link\">",
"     Pegylated interferon alfa-2b",
"    </a>",
"    has been approved by the FDA for use in children three years and older (60",
"    <span class=\"nowrap\">",
"     mcg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once weekly, maximum dose 1.5",
"    <span class=\"nowrap\">",
"     micrograms/kg)",
"    </span>",
"    in combination with ribavirin (15",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in two divided doses) (",
"    <a class=\"graphic graphic_table graphicRef61219 \" href=\"UTD.htm?14/14/14572\">",
"     table 1",
"    </a>",
"    ).",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/61/8152?source=see_link\">",
"     Pegylated interferon alfa-2a",
"    </a>",
"    (180",
"    <span class=\"nowrap\">",
"     micrograms/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    weekly, maximum dose 180 micrograms) can also be used in combination with ribavirin in children five years and older.",
"   </p>",
"   <p>",
"    The treatment duration varies by genotype, as it does for adults [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For genotype 2 or 3, we typically treat for 24 weeks (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For genotype 1, we use the same algorithm that is used for adults to determine the length of treatment. Treatment is planned for 48 weeks, but may be discontinued earlier in those who do not achieve an early virologic response (ie, at least a 2-log decline from baseline of the HCV RNA level at week 12), or extended to 72 weeks for those with a slow virologic response. These parameters for deciding on treatment length are discussed in detail separately (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=see_link&amp;anchor=H148834087#H148834087\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Patients not receiving a protease inhibitor'",
"      </a>",
"      ). If possible, treatment of children with HCV genotype 1 might be deferred until triple therapy is available for children, or done sooner if under the auspices of a clinical trial (see",
"      <a class=\"local\" href=\"#H22932936\">",
"       'Triple therapy'",
"      </a>",
"      above). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     COUNSELING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Prevention of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary strategies to prevent HCV infection should focus on perinatal transmission, which, as noted above, is the most common cause of HCV acquisition in children. Universal testing of pregnant women for HCV is not recommended. Optimal methods to reduce the risk of transmission in women known to be HCV infected are incompletely understood, although several factors associated with an increased risk of transmission have been described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HCV is not spread within households, school, or daycare settings [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Because it is transmitted by blood, it may be prudent to avoid sharing razors, toothbrushes, nail clippers, and other implements that may be contaminated with blood of an infected individual. Although HCV can be detected in low levels in saliva [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/75\">",
"     75",
"    </a>",
"    ], the risk of transmission through saliva appears to be minimal. It is not necessary to avoid sharing eating utensils, drinking glasses, or towels.",
"   </p>",
"   <p>",
"    Prevention of new HCV infections in older children and adolescents focuses mostly on counseling for high-risk behaviors. While commercial body piercing and tattooing are not clearly associated with increased risk, self-tattooing and self-piercing with shared needles are common practices and should be discouraged. Similarly, the risk of transmission is increased with the use of intravenous drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intranasal cocaine because of sharing of potentially contaminated equipment. The risk of sexual transmission, albeit low, may not be appreciated by teenagers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/2/6186/abstract/14\">",
"     14",
"    </a>",
"    ]. Sex with multiple partners is a risk factor for HCV infection, but may not be directly responsible for transmission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link&amp;anchor=H9#H9\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\", section on 'Sexual or household contact'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Minimizing risk for disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following general measures are recommended for patients with chronic HCV:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients should avoid alcohol consumption. Alcohol promotes the progression of chronic HCV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9496?source=see_link\">",
"       \"Hepatitis C and alcohol\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients should be immunized against hepatitis A and hepatitis B, if not already immune. They should also receive standard immunizations that are applicable to an otherwise healthy population. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=see_link\">",
"       \"Immunizations for patients with chronic liver disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"       \"Standard immunizations for children and adolescents\", section on 'Overview'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no evidence that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/15/19705?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use promotes disease progression in patients with HCV and normal liver function, but it is appropriate to remind patients to use no more than recommended doses. Patients with advanced liver disease (HCV or other) should avoid non-steroidal anti-inflammatory drugs such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of HCV infection is lower in children than in adults. Perinatal transmission is by far the most common source of infection in children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"       \"Vertical transmission of hepatitis C virus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Testing for HCV is generally recommended in children of mothers known to be infected with HCV or with a history of intravenous drug use. Testing also should be performed in children who received blood products prior to 1992. Testing also is recommended for children who are international adoptees or refugees. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCV generally progresses slowly in children, although there are exceptions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in adults, treatment response rates to combination therapy with pegylated interferon (or standard interferon) and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/59/12216?source=see_link\">",
"       ribavirin",
"      </a>",
"      are higher in individuals with HCV genotype 2 or 3 as compared to genotype 1. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pegylated interferon plus ribavirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with chronic HCV infection, the decision about whether to evaluate with a liver biopsy depends on the HCV genotype and the child's age (or duration of HCV infection if horizontally acquired) (",
"      <a class=\"graphic graphic_algorithm graphicRef72599 \" href=\"UTD.htm?31/50/32558\">",
"       algorithm 1",
"      </a>",
"      ). For those with genotype 2 or 3 who are older than three years, we generally proceed to treatment without liver biopsy. For children with genotype 1, we encourage treatment, but offer a liver biopsy if families would like to have additional prognostic information before making a treatment decision. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Liver biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with HCV genotype 2 or 3, or for those with genotype 1 and moderate or severe histopathology, we recommend treatment rather than observation (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Decision to treat'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'How to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HCV genotype 1 and mild histopathologic features, we encourage treatment if the child is older than age three, but it is also reasonable to observe without treatment. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Decision to treat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For children with HCV genotype 1, treatment might also be deferred until triple therapy is available for children, or done sooner in the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H22932936\">",
"       'Triple therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients embarking on treatment for HCV we recommend treatment with combination therapy rather than interferon monotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ) (",
"      <a class=\"graphic graphic_table graphicRef61219 \" href=\"UTD.htm?14/14/14572\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pegylated interferon plus ribavirin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       'How to treat'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/1\">",
"      Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/2\">",
"      Jhaveri R. Diagnosis and management of hepatitis C virus-infected children. Pediatr Infect Dis J 2011; 30:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/3\">",
"      Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/4\">",
"      Delgado-Borrego A, Smith L, Jonas MM, et al. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr 2012; 161:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/5\">",
"      Resti M, Azzari C, Rossi ME, et al. Hepatitis C virus antibodies in a long-term follow-up of beta-thalassaemic children with acute and chronic non-A non-B hepatitis. Eur J Pediatr 1992; 151:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/6\">",
"      Lai ME, De Virgilis S, Argiolu F, et al. Evaluation of antibodies to hepatitis C virus in a long-term prospective study of posttransfusion hepatitis among thalassemic children: comparison between first- and second-generation assay. J Pediatr Gastroenterol Nutr 1993; 16:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/7\">",
"      Blanchette VS, Vorstman E, Shore A, et al. Hepatitis C infection in children with hemophilia A and B. Blood 1991; 78:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/8\">",
"      Locasciulli A, Gornati G, Tagger A, et al. Hepatitis C virus infection and chronic liver disease in children with leukemia in long-term remission. Blood 1991; 78:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/9\">",
"      Rossetti F, Cesaro S, Pizzocchero P, et al. Chronic hepatitis B surface antigen-negative hepatitis after treatment of malignancy. J Pediatr 1992; 121:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/10\">",
"      Jonas MM, Zilleruelo GE, LaRue SI, et al. Hepatitis C infection in a pediatric dialysis population. Pediatrics 1992; 89:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/11\">",
"      Greco M, Cristiano K, Leozappa G, et al. Hepatitis C infection in children and adolescents on haemodialysis and after renal transplant. Pediatr Nephrol 1993; 7:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/12\">",
"      Nelson SP, Jonas MM. Hepatitis C infection in children who received extracorporeal membrane oxygenation. J Pediatr Surg 1996; 31:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/13\">",
"      Ni YH, Chang MH, Lue HC, et al. Posttransfusion hepatitis C virus infection in children. J Pediatr 1994; 124:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/14\">",
"      Murray KF, Richardson LP, Morishima C, et al. Prevalence of hepatitis C virus infection and risk factors in an incarcerated juvenile population: a pilot study. Pediatrics 2003; 111:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/15\">",
"      Khalifa AS, Mitchell BS, Watts DM, et al. Prevalence of hepatitis C viral antibody in transfused and nontransfused Egyptian children. Am J Trop Med Hyg 1993; 49:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/16\">",
"      Tanaka E, Kiyosawa K, Sodeyama T, et al. Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. Am J Trop Med Hyg 1992; 46:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/17\">",
"      Lee SD, Chan CY, Wang YJ, et al. Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology 1991; 13:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/18\">",
"      Gessoni G, Manoni F. Prevalence of anti-hepatitis C virus antibodies among teenagers in the Venetian area: a seroepidemiological study. Eur J Med 1993; 2:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/19\">",
"      Lee WS, Ng KP. Seroprevalence of anti-HCV in an urban child population: a preliminary study from Kuala Lumpur. Singapore Med J 2001; 42:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/20\">",
"      al-Faleh FZ, Ayoola EA, al-Jeffry M, et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community-based study. Hepatology 1991; 14:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/21\">",
"      Drobeniuc J, Hutin YJ, Harpaz R, et al. Prevalence of hepatitis B, D and C virus infections among children and pregnant women in Moldova: additional evidence supporting the need for routine hepatitis B vaccination of infants. Epidemiol Infect 1999; 123:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/22\">",
"      Ngatchu T, Stroffolini T, Rapicetta M, et al. Seroprevalence of anti-HCV in an urban child population: a pilot survey in a developing area, Cameroon. J Trop Med Hyg 1992; 95:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/23\">",
"      El-Raziky MS, El-Hawary M, Esmat G, et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J Gastroenterol 2007; 13:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/24\">",
"      Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/25\">",
"      Bortolotti F, Iorio R, Jorio R, et al. Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. J Hepatol 2007; 46:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/26\">",
"      Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002; 99:4588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/27\">",
"      Casiraghi MA, De Paschale M, Roman&ograve; L, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004; 39:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/28\">",
"      Matsuoka S, Tatara K, Hayabuchi Y, et al. Serologic, virologic, and histologic characteristics of chronic phase hepatitis C virus disease in children infected by transfusion. Pediatrics 1994; 94:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/29\">",
"      Vogt M, Lang T, Fr&ouml;sner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999; 341:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/30\">",
"      Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European Paediatric Hepatitis C Virus Infection. J Infect Dis 2000; 181:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/31\">",
"      Mohan P, Colvin C, Glymph C, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr 2007; 150:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/32\">",
"      Matsuoka S, Tatara K, Hayabuchi Y, et al. Post-transfusion chronic hepatitis C in children. J Paediatr Child Health 1994; 30:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/33\">",
"      European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin Infect Dis 2005; 41:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/34\">",
"      Jonas MM, Baron MJ, Bresee JS, Schneider LC. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics 1996; 98:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/35\">",
"      Jara P, Resti M, Hierro L, et al. Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children. Clin Infect Dis 2003; 36:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/36\">",
"      Badizadegan K, Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/37\">",
"      Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998; 115:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/38\">",
"      Goodman ZD, Makhlouf HR, Liu L, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/39\">",
"      Bortolotti F, Verucchi G, Camm&agrave; C, et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/40\">",
"      Birnbaum AH, Shneider BL, Moy L. Hepatitis C in children. N Engl J Med 2000; 342:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/41\">",
"      Vogt M, M&uuml;hlbauer F, Braun SL, et al. Prevalence and risk factors of hepatitis C infection after cardiac surgery in childhood before and after blood donor screening. Infection 2004; 32:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/42\">",
"      Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/43\">",
"      Clemente MG, Congia M, Lai ME, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994; 125:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/44\">",
"      Makris M, Preston FE, Rosendaal FR, et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/45\">",
"      Goedert JJ, Eyster ME, Lederman MM, et al. End-stage liver disease in persons with hemophilia and transfusion-associated infections. Blood 2002; 100:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/46\">",
"      Aric&ograve; M, Maggiore G, Silini E, et al. Hepatitis C virus infection in children treated for acute lymphoblastic leukemia. Blood 1994; 84:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/47\">",
"      Locasciulli A, Testa M, Pontisso P, et al. Prevalence and natural history of hepatitis C infection in patients cured of childhood leukemia. Blood 1997; 90:4628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/48\">",
"      Strickland DK, Riely CA, Patrick CC, et al. Hepatitis C infection among survivors of childhood cancer. Blood 2000; 95:3065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/49\">",
"      Giacchino R, Tasso L, Timitilli A, et al. Vertical transmission of hepatitis C virus infection: usefulness of viremia detection in HIV-seronegative hepatitis C virus-seropositive mothers. J Pediatr 1998; 132:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/50\">",
"      Ceci O, Margiotta M, Marello F, et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J Pediatr Gastroenterol Nutr 2001; 33:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/51\">",
"      Palomba E, Manzini P, Fiammengo P, et al. Natural history of perinatal hepatitis C virus infection. Clin Infect Dis 1996; 23:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/52\">",
"      Bortolotti F, Resti M, Giacchino R, et al. Hepatitis C virus infection and related liver disease in children of mothers with antibodies to the virus. J Pediatr 1997; 130:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/53\">",
"      Delgado-Borrego A, Healey D, Negre B, et al. Influence of body mass index on outcome of pediatric chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2010; 51:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/54\">",
"      El-Kamary SS, Serwint JR, Joffe A, et al. Prevalence of hepatitis C virus infection in urban children. J Pediatr 2003; 143:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/55\">",
"      Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/56\">",
"      Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31:751.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Medical evaluation of internationally adopted children for infectious diseases. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th ed, Pickering LK, Baker CJ, Kimberlin DW, Long SS, Eds (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/58\">",
"      Jonas MM. Finding adolescents and young adults with transfusion-associated hepatitis C: looking forward to looking back. Arch Pediatr Adolesc Med 2007; 161:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/59\">",
"      Cagle HH, Jacob J, Homan CE, et al. Results of a general hepatitis C lookback program for persons who received blood transfusions in a neonatal intensive care unit between January 1975 and July 1992. Arch Pediatr Adolesc Med 2007; 161:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/60\">",
"      Kage M, Fujisawa T, Shiraki K, et al. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology 1997; 26:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/61\">",
"      Murray KF, Finn LS, Taylor SL, et al. Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2005; 41:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/62\">",
"      Gonz&aacute;lez-Peralta RP, Langham MR Jr, Andres JM, et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2009; 48:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/63\">",
"      Wirth S, Pieper-Boustani H, Lang T, et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/64\">",
"      Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/65\">",
"      Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/66\">",
"      Sokal EM, Bourgois A, St&eacute;phenne X, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J Hepatol 2010; 52:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/67\">",
"      Jonas MM, Balistreri W, Gonzalez-Peralta RP, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology 2012; 56:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/68\">",
"      Rodrigue JR, Balistreri W, Haber B, et al. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology 2011; 53:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/69\">",
"      Narkewicz MR, Rosenthal P, Schwarz KB, et al. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr 2010; 51:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/70\">",
"      Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/71\">",
"      Gonz&aacute;lez-Peralta RP, Kelly DA, Haber B, et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005; 42:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/72\">",
"      Jacobson KR, Murray K, Zellos A, Schwarz KB. An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34:52.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Hepatitis C. In: Red Book: 2009 Report of the Committee on Infectious Diseases, 28th, Pickering LK (Ed), American Academy of Pediatrics, Elk Grove Village 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/74\">",
"      Vegnente A, Iorio R, Saviano A, et al. Lack of intrafamilial transmission of hepatitis C virus in family members of children with chronic hepatitis c infection. Pediatr Infect Dis J 1994; 13:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/2/6186/abstract/75\">",
"      Suzuki T, Omata K, Satoh T, et al. Quantitative detection of hepatitis C virus (HCV) RNA in saliva and gingival crevicular fluid of HCV-infected patients. J Clin Microbiol 2005; 43:4413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5944 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-8D972B75FE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6186=[""].join("\n");
var outline_f6_2_6186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Spontaneous clearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Advanced disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Factors associated with disease progression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Reason for transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Perinatal transmission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HCV genotyping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serum aminotransferases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Acute infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chronic infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Pegylated interferon plus ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Standard interferon plus ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Interferon monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22932936\">",
"      - Triple therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Decision to treat",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - How to treat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Prevention of transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Minimizing risk for disease progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5944\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5944|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/50/32558\" title=\"algorithm 1\">",
"      Approach HCV child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5944|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/63/12279\" title=\"picture 1\">",
"      HCV hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/0/33799\" title=\"picture 2\">",
"      HCV hepatitis Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/25/21910\" title=\"picture 3\">",
"      HCV cirrhosis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5944|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/14/14572\" title=\"table 1\">",
"      PegIFN Rx child HCV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18554?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/17/9496?source=related_link\">",
"      Hepatitis C and alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8569?source=related_link\">",
"      Immunizations for patients with chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=related_link\">",
"      Vertical transmission of hepatitis C virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_2_6187="Cutan react EGFR inhib";
var content_f6_2_6187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57215&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cutaneous reactions associated with epidermal growth factor receptor inhibitors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reported cutaneous effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cetuximab",
"       </td>",
"       <td rowspan=\"5\">",
"        <p>",
"         Abnormal scalp, facial hair, and/or eyelash growth;",
"        </p>",
"        <p>",
"         papulopustular (acneiform) rash;",
"        </p>",
"        <p>",
"         paronychia with or without pyogenic granuloma;",
"        </p>",
"        <p>",
"         telangiectasias; xerosis; pruritus; purpuric xerotic dermatitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erlotinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gefitinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lapatinib",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panitumumab",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6187=[""].join("\n");
var outline_f6_2_6187=null;
var title_f6_2_6188="Crying framework";
var content_f6_2_6188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77427&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lester's framework for colic and excessive crying",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Colic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Meets the \"rule of three\" criterion:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Greater than 3 hours per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Greater than 3 days per week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lasts at least 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Includes the additional four characteristics:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Paroxysmal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Qualitatively different from normal crying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Associated with hypertonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Inconsolability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The infant is normal when not colicky",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        First few weeks of life are unremarkable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Excessive crying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meets the definition of colic except does not have the additional four characteristics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Early onset",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colic and/or excessive crying starts at or shortly after birth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Persistent crying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant fusses or cries virtually all the time that he or she is awake (except perhaps during feeding)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infant is described as never being happy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May accompany colic or excessive crying",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lester, BM. In: Colic and Excessive Crying. Report of the 105th Ross Conference on Pediatric Research, Lester, BM, Barr, RG (Eds), Ross Products Division,Columbus, OH, 1997, p.18.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6188=[""].join("\n");
var outline_f6_2_6188=null;
var title_f6_2_6189="Comparison of bronchiolitis I";
var content_f6_2_6189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50736%7EPULM%2F60031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50736%7EPULM%2F60031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proliferative versus constrictive bronchiolitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Proliferative bronchiolitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Constrictive bronchiolitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histopathologic manifestations",
"       </td>",
"       <td>",
"        <p>",
"         Common finding",
"        </p>",
"        <p>",
"         Nonspecific reparative reaction to bronchiolar injury",
"        </p>",
"        <p>",
"         Organizing intraluminal exudate",
"        </p>",
"        <p>",
"         Most prominent in alveolar ducts",
"        </p>",
"        <p>",
"         Inflammatory changes in surrounding alveolar walls",
"        </p>",
"        <p>",
"         Foamy macrophages in alveoli",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Very uncommon finding",
"        </p>",
"        <p>",
"         Obliterans not a constant feature",
"        </p>",
"        <p>",
"         Variety",
"of histologic changes: bronchiolar inflammation to progressive",
"concentric fibrosis; smooth muscle hyperplasia, bronchioloectasia with",
"mucus stasis; distortion and fibrosis of small airway walls with",
"bronchial metaplasia extending onto peribronchiolar alveolar septa",
"        </p>",
"        <p>",
"         Follicular bronchitis (lymphoid hyperplasia)",
"        </p>",
"        <p>",
"         Cellular bronchiolitis",
"        </p>",
"        <p>",
"         Diffuse panbronchiolitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiographic abnormalities",
"       </td>",
"       <td>",
"        <p>",
"         Bilateral patchy airspace opacities",
"        </p>",
"        <p>",
"         Interstitial opacities",
"        </p>",
"        <p>",
"         Small rounded opacities",
"        </p>",
"        <p>",
"         Opacities may be recurrent and migratory",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         May be normal",
"        </p>",
"        <p>",
"         Progressive increase in lung volume on serial radiographs",
"        </p>",
"        <p>",
"         HRCT scan may show marked heterogeneity of lung density",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary function",
"       </td>",
"       <td>",
"        Restrictive defect (a mixed pattern may be seen)",
"       </td>",
"       <td>",
"        Obstructive defect with hyperinflation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from King, TE Jr, Clin Chest Med 1993; 14:607.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proliferative versus constrictive bronchiolitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Proliferative bronchiolitis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Constrictive bronchiolitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Selected clinical syndromes",
"      </td>",
"      <td>",
"       <p>",
"        Cryptogenic organizing pneumonia (idiopathic bronchiolitis obliterans with organizing pneumonia)",
"       </p>",
"       <p>",
"        Collagen vascular disease (eg, dermatomyositis, SLE)",
"       </p>",
"       <p>",
"        Chronic \"organizing\" pneumonia (especially influenza, Mycoplasma, Pneumocystis carinii)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Allograft recipients (bone marrow, heart-lung, lung)",
"       </p>",
"       <p>",
"        Collagen vascular disease (rheumatoid arthritis)",
"       </p>",
"       <p>",
"        Post-infectious (especially respiratory syncytial virus, adenovirus, influenza, parainfluenza, Mycoplasma)",
"       </p>",
"       <p>",
"        Inhaled toxins (eg, nitrogen dioxide, sulfur dioxide, ammonia, chlorine, phosgene)",
"       </p>",
"       <p>",
"        Drugs (eg, penicillamine, lomustine)",
"       </p>",
"       <p>",
"        Cigarette smoke",
"       </p>",
"       <p>",
"        Mineral dust airway disease",
"       </p>",
"       <p>",
"        Idiopathic",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Natural history",
"      </td>",
"      <td>",
"       Glucocorticoid responsive and usually reversible",
"      </td>",
"      <td>",
"       Relatively glucocorticoid unresponsive and usually progressive, with the development of irreversible airflow obstruction and air trapping",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from King, TE Jr, Clin Chest Med 1993; 14:607.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6189=[""].join("\n");
var outline_f6_2_6189=null;
var title_f6_2_6190="Prostate ca incidence over time";
var content_f6_2_6190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Prostate cancer: Changes over time average annual age-adjusted incidence and mortality rates in the United States, 1975-2007",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 370px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: SEER Program.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6190=[""].join("\n");
var outline_f6_2_6190=null;
var title_f6_2_6191="Proximal phalanx condylar fracture lateral xray";
var content_f6_2_6191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Condylar fracture of the proximal phalanx: Lateral x-ray",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 517px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral radiograph shows a condylar fracture of the proximal phalanx. Although less apparent here than on the AP view, the fracture is reflected in the irregularity of the cortex before the white arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_2_6191=[""].join("\n");
var outline_f6_2_6191=null;
